NZ548467A

NZ548467A - Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl] sulphonamide, their preparation and their application in therapeutics

Info

Publication number: NZ548467A
Application number: NZ54846706A
Authority: NZ
Inventors: Francis Barth; Christian Congy; Serge Martinez; Philippe Pointeau; Murielle Rinaldi-Carmona
Original assignee: Sanofi Aventis
Priority date: 2006-07-12
Filing date: 2006-07-12
Publication date: 2008-03-28

Abstract

Disclosed are derivatives of N-[1,5-diphenyl-4-methyl-1H-pyrazol-3-yl)methyl]sulphonamide of formula (I), which possess CB1 cannabinoid receptor antagonist properties, localized at the central and/or peripheral level.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 548467 54 S 467 *10052154775* NEW ZEALAND PATENTS ACT, 1953 No: Date: COMPLETE SPECIFICATION DERIVATIVES OF N-[(l,5-DIPHENYL-lH-PYRAZOL-3-YL)METHYL] SULPHONAMIDE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS We, SANOFI-AVENTIS, a French company of 174 Avenue de France, 75013 Paris, France, do hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: -1 - INTELLECTUAL PROPERTY OFFICE OF N.Z. 12 JUL 2006 MOHVID 245407694016_1.DOC DERIVATIVES OF N-[(l,5-DIPHENYL-l//-PYRAZOL-3-YL)METHYL] SULPHONAMIDE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS. The present invention relates to derivatives of N-[(l,5-diphenyl-l//-pyrazol-3-yl)methyl]sulphonamide, their preparation and their application in therapeutics. Diphenylpyrazole derivatives displaying affinity for the CBi cannabinoid receptors were described notably in patents EP 0 576 357, EP 0 656 354 and US 5 624 941. International patent application W02005/073 197 describes derivatives of N-[l,5-dipllenyl-4-methyl-l//-pyrazol-3-yl)methyl]sulphonamide, antagonists of the CBi cannabinoid receptors. Novel derivatives of N-[(l,5-diphenyl-l//-pyrazol-3-yl)methyl]sulphonamide have now been found which possess CBi cannabinoid receptor antagonist properties, localized at the central and/or peripheral level. The present invention relates to compounds corresponding to the formula (I): in which: Ri represents . a (Ci-ci2)alkyl, unsubstituted or substituted one or more times with substituents selected independently from a fluorine atom, a hydroxyl, a (Ci-c4)alkoxy, a (Ci-c4)alkylthio, a phenoxy, a trifluoromethoxy radical, a difluoromethoxy radical, a difluoromethylthio radical, a trifluoromethylthio radical; . a non-aromatic (c3-c12) carbocyclic radical, unsubstituted or substituted one or more times with substituents selected independently from a (Ci-c4)alkyl, a (Ci-c4)alkoxy, a (Ci-c4)alkylthio, a fluorine atom, a hydroxyl, a trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio, difluoromethylthio radical; . a methyl substituted with a non-aromatic (c3-c12) carbocyclic radical, unsubstituted or substituted one or more times with substituents selected independently from a (Ci-c4)alkyl, a (Ci-c4)alkoxy, a (Ci-c4)alkylthio, a 3 fluorine atom, a hydroxyl, a trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio, difluoromethylthio radical; . a phenyl, benzyl, benzhydryl, or benzhydrylmethyl radical, in which each phenyl group is unsubstituted or substituted one or more times with substituents selected 5 independently from a halogen atom, a hydroxyl, a methylenedioxy, a cyano, a nitro, a (Ci-c4)alkylcarbonyl group or an Alk, OAlk, S(0)nAlk or 0S(0)nAlk group; . a phenyl radical substituted with a heterocyclic radical selected from pyrrolyl, imidazolyl, pyridyl or pyrazolyl, said heterocyclic radical being unsubstituted or 10 substituted one or more times with one or more substituents selected independently from a halogen atom or a (Ci-c4)alkyl group; . a phenyl radical substituted with a phenyl or a phenoxy in which each phenyl group is unsubstituted or substituted one or more times with substituents selected independently from a halogen atom, a hydroxyl, a methylenedioxy, a 15 cyano, a nitro, a (Ci-c4)alkylcarbonyl group or an Alk, OAlk, S(0)nAlk or 0S(0)„Alk group; . a thienyl, furyl, oxazolyl, thiazolyl, imidazolyl, pyrrolyl, or pyridyl group, said radical being unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Ci-c4)alkyl, a trifluoromethyl group; 20 . a tetrahydronaphthalenyl or a naphthyl unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Ci-C4)alkyl, a di(Ci-c4)alkylamino or a trifluoromethyl group; . a 2,3-dihydrobenzofuranyl unsubstituted or substituted one or more times with a (Ci-C4)alkyl group; 25 . an indol-2-yl or an N-methylindol-2-yl; - R.2 represents a hydrogen atom, a (Ci-c4)alkyl or a (Ci-c4)alkylsulphonyl group; - R-3 represents a cyano, a hydroxyl, a (Ci-c4)alkoxy, a cyanomethyl, a hydroxymethyl, a (Ci-c4)alkoxymethyl, a fluoromethyl, a tetrazolylmethyl, an N-(methyl)tetrazolylmethyl, a tetrazolyl, an N-(methyl)tetrazolyl, a CONR.6R7 group, 30 a CH2S(0)n(Ci-C4)alkyl group, a COORg group or a CH2NR6R7 group; R4 and R5 each represent independently a phenyl, unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Ci-C7)alkyl group unsubstituted or substituted one or more times with a fluorine atom, an OAlk, S(0)nAlk or 0S(0)nAlk group; 35 R6 and R7 each represent independently a hydrogen atom or a (Ci-c4)alkyl or R$ and R7 together with the nitrogen atom to which they are bound constitute a 4 heterocyclic radical selected from pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl unsubstituted or substituted one or more times with a (Ci-Chalky 1; R.8 represents a (Ci-c4)alkyl; n represents 0, 1 or 2; 5 - Alk represents a (Ci-C4)alkyl unsubstituted or substituted one or more times with a fluorine atom. The compounds of formula (I) can contain one or more asymmetric carbon atoms. They can therefore be in the form of enantiomers or of diastereoisomers. These enantiomers, diastereoisomers as well as mixtures thereof, including the racemic 10 mixtures, form part of the invention. The compounds of formula (I) can be in the form of bases or acid addition salts. Such acid addition salts form part of the invention. These salts are advantageously prepared with pharmaceutically acceptable acids but the salts of other acids that can be used for the purification or isolation of the 15 compounds of formula (I) also form part of the invention. The compounds of formula (I) can also be in the form of hydrates or of solvates, i.e. in the form of associations or of combinations with one or more water molecules or with a solvent. Such hydrates and solvates also form part of the invention. More specifically, in a first aspect, the present invention provides a compound of 20 formula (I): R, O I II r3 ^ch2—N—S—R, 2"1 O r4 n (I) r5 in which: - Ri represents . a (Ci-ci2)alkyl, unsubstituted or substituted one or more times with substituents 25 selected independently from a fluorine atom, a hydroxyl, a (Ci-c4)alkoxy, a (Ci-c4)alkylthio, a phenoxy, a trifluoromethoxy radical, a difluoromethoxy radical, a difluoromethylthio radical, a trifluoromethylthio radical; . a non-aromatic (c3-c12) carbocyclic radical, unsubstituted or substituted one or more times with substituents selected independently from a (Ci-c4)alkyl, a (Ci-c4)alkoxy, a 30 (Ci-C4)alkylthio, a fluorine atom, a hydroxyl, a trifluoromethyl radical, a 1253799-1 INTELLECTUAL PRO OFHCF V / 1 (J C:X 2UU/ RECEIVE, 5 difluoromethyl radical, a trifluoromethoxy radical, a difluoromethoxy, a trifluoromethylthio radical, a difluoromethylthio radical; . a methyl substituted with a non-aromatic (c3-c12) carbocyclic radical, unsubstituted or substituted one or more times with substituents selected independently from a (Ci-5 c4)alkyl, a (Ci-c4)alkoxy, a (Ci-c4)alkylthio, a fluorine atom, a hydroxyl, a trifluoromethyl radical, a difluoromethyl radical, a trifluoromethoxy radical, a difluoromethoxy radical, a trifluoromethylthio radical, a difluoromethylthio radical; . a phenyl, benzyl, benzhydryl, or benzhydrylmethyl radical, in which each phenyl group is unsubstituted or substituted one or more times with substituents selected 10 independently from a halogen atom, a hydroxyl, a methylenedioxy, a cyano, a nitro, a (Ci-C4)alkylcarbonyl group or an Alk, OAlk, S(0)nAlk or 0S(0)nAlk group; . a phenyl radical substituted with a heterocyclic radical selected from pyrrolyl, imidazolyl, pyridyl or pyrazolyl, said heterocyclic radical being unsubstituted or substituted one or more times with one or more substituents selected independently 15 from a halogen atom or a (Ci-c4)alkyl group; . a phenyl radical substituted with a phenyl or a phenoxy in which each phenyl group is unsubstituted or substituted one or more times with substituents selected independently from a halogen atom, a hydroxyl, a methylenedioxy, a cyano, a nitro, a (Ci-c4)alkylcarbonyl group or an Alk, OAlk, S(0)nAlk or 0S(0)nAlk group; 20 . a thienyl, furyl, oxazolyl, thiazolyl, imidazolyl, pyrrolyl, or pyridyl radical, said radical being unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Ci-c4)alkyl, a trifluoromethyl group; . a tetrahydronaphthalenyl or a naphthyl unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Ci-c4)alkyl, a di(C[-25 c4)alkylamino or a trifluoromethyl group; . a 2,3-dihydrobenzofuranyl unsubstituted or substituted one or more times with a (Ci-C4)alkyl group; . an indol-2-yl or an N-methylindol-2-yl; - R2 represents a hydrogen atom, a (C]-c4)alkyl or a (C]-c4)alkylsulphonyl group; 30 - R3 represents a cyano, a hydroxyl, a (Ci-c4)alkoxy, a cyanomethyl, a hydroxymethyl, a (Ci-c4)alkoxymethyl, a fluoromethyl, a tetrazolylmethyl, an N-(methyl)tetrazolylmethyl, a tetrazolyl, an N-(methyl)tetrazolyl, a CONR6R7 group, a CH2S(0)n(Ci-C4)alkyl group, a COORg group or a CH2NR6R7 group; - R4 and R5 each represent independently a phenyl unsubstituted or substituted with 35 one or more substituents selected independently from a halogen atom, a (Ci-c7)alkyl 1253799-1 INTELLECTUAL PROPERTV OFFICE OP N / I II P ' RECEIVE 6 group unsubstituted or substituted one or more times with a fluorine atom, an OAlk, S(0)nAlk or 0S(0)nAlk group; - R<s and R7 each represent independently a hydrogen atom or a (Ci-C4)alkyl or R6 and R7 together with the nitrogen atom to which they are bound constitute a heterocyclic 5 radical selected from pyrrolidinyl, piperidinyl, morpholinyl, and piperazinyl unsubstituted or substituted one or more times with a (Ci-c4)alkyl; - R8 represents a (Ci-c4)alkyl; - n represents 0, 1 or 2; - Alk represents a (Ci-c4)alkyl unsubstituted or substituted one or more times with a 10 fluorine atom; or an acid addition salt, a hydrate, or a solvate thereof. In a further aspect, the present invention provides a method of preparing a compound of formula (I), wherein a compound of formula (II): -NH (II) 15 in which R2, R4, R5 are as defined in Claim 1 and R'3 represents R3 or a precursor of r3, is reacted, in the presence of a base, in a solvent, with a sulphonyl halide of formula HalS02Ri, in which Rj is as defined in Claim 1 and Hal represents a halogen atom; and if applicable, the compound obtained of formula (III): r? I2 ch2-n-so2-r} (III) 20 in which R'3 is R3 or is a precursor of r3, is converted to a compound of formula (I). In a yet further aspect, the present invention provides a compound of formula (I), or an acid addition salt, a hydrate, or a solvate thereof, for use as a medicament. In another aspect, the present invention provides a pharmaceutical composition, comprising a compound of formula (I), or an acid addition salt, a hydrate, or a solvate 25 thereof, and at least one pharmaceutically acceptable excipient. 1253799-1 INTELLECTUAL PROPERTY ; OFFICE OF NZ j 1 (j Ot'C 2007 R E C E I V E C 7 In another aspect, the present invention provides use of a compound of formula (I), for the preparation of a medicinal product for the treatment or the prevention of a disease in which the CBi receptors are involved. In another aspect, the present invention provides a compound of formula (I), 5 when prepared by a method of the invention. The term "comprising" as used in this specification means "consisting at least in part of'. When interpreting each statement in this specification that includes the term "comprising", features other than that or those prefaced by the term may also be present. Related terms such as "comprise" and "comprises" are to be interpreted in 10 the same manner."Halogen atom" means an atom of bromine, of chlorine, of fluorine or of iodine. "(Ci-c4)alkyl or respectively (Ci-c7)alkyl or (Ci-ci2)alkyl" means a linear or branched alkyl radical of one to four carbon atoms or respectively of one to seven or of one to twelve carbon atoms, such as the methyl, ethyl, propyl, isopropyl, butyl, 15 isobutyl, sec-butyl, /er/-butyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, etc. radical. "(Ci-c4)alkyl substituted one or more times with a fluorine atom" means in particular the difluoromethyl, trifluoromethyl, difluoromethyl, trifluoroethyl groups. "(Ci-c4)alkoxy" means a linear or branched alkoxy radical of one to four carbon atoms or respectively of one to five carbon atoms, such as the methoxy, ethoxy, 20 propoxy, isopropoxy, butoxy, .yeobutoxy, terf-butoxy radical. "(c3-c7)cycloalkyl" means a cyclic alkyl group of 3 to 7 carbon atoms, such as the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl group. "Tetrazolyl" means atetrazol-l-yl, tetrazol-2-yl or tetrazol-5-yl radical. More particularly, the present invention relates to compounds corresponding to 25 formula (I): in which: - Ri represents . a (Ci-c7)alkyl; . a (c3-c7)cycloalkyl unsubstituted or substituted one or more times with a (Q-30 C4)alkyl group; . a (c3-c7)cycloalkylmethyl unsubstituted or substituted one or more times on the carbocycle with a (Ci-c4)alkyl; . a phenyl unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Cj-c4)alkyl, a (Ci-c4)alkoxy, a cyano, a 35 trifluoromethyl group, a trifluoromethoxy group, an S(0)nAlk group, a (Ci- c4)alkylcarbonyl group, a phenyl; 1253799-1 INTELLECTUAL PROPERTY OFFICE OF N 2 11) DEC 200/ RECEIVED 8 10 15 20 • 25 30 . a benzyl unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Ci-c4)alkyl, a (Ci-c4)alkoxy; a trifluoromethyl group; . a thienyl, furyl, oxazolyl, thiazolyl, imidazolyl radical, said radical being unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (CpC^alkyl, a trifluoromethyl group; . a naphthyl unsubstituted or substituted with one or more substituents selected independently from a (Ci-c4)alkyl, a di(Ci-c4)alkylamino; . a 2,3-dihydrobenzofuranyl unsubstituted or substituted one or more times with a (Ci-c4)alkyl group; - R-2 represents a hydrogen atom or a (Ci-c4)alkyl; - R-3 represents a cyano, a hydroxyl, a (Ci-c4)alkoxy, a cyanomethyl, a hydroxymethyl, a (Ci-c4)alkoxymethyl, a fluoromethyl, a tetrazolylmethyl, an N-(methyl)tetrazolylmethyl, a tetrazolyl, an N-(methyl)tetrazolyl, a CONR^R? group, a ch2s(0)„Alk group, a COORg group; Rt and R5 each represent independently a phenyl unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Cj-C7)alkyl, a (Ci-c4)alkoxy, a trifluoromethyl group or an S(0)nAlk group; Rg and R7 each represent independently a hydrogen atom or a (Ci-c4)alkyl or R6 and R7 together with the nitrogen atom to which they are bound constitute a heterocyclic radical selected from pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl unsubstituted or substituted one or more times with a (Ci-c4)alkyl; Rg represents a (Ci-c4)alkyl; n represents 0,1 or 2; Alk represents a (Ci-c4)alkyl. Among the compounds of formula (I) according to the invention, a distinction is made between: - the compounds of formula I a in which r3 is a cyano; - the compounds of formula Ig in which R3 is a hydroxyl; - the compounds of formula iq in which R3 is a (Ci-c4)alkoxy; - the compounds of formula Ij) in which r3 is a cyanomethyl; - the compounds of formula Ig; in which R3 is a hydroxymethyl; - the compounds of formula Ip in which R3 is a (Ci-c4)alkoxymethyl; - the compounds of formula Iq in which R3 is a fluoromethyl; - the compounds of formula ih in which R3 is a CH2S(0)„Alk group; - the compounds of formula Ij in which r3 is a CONR^R? group; 1253799-1 INTELLECTUAL property office OF M 2 1 u DEC 2007 p<=CcIV 9 - the compounds of formula Ij in which R3 is a COORg; - the compounds of formula Ij£ in which R3 is a tetrazol-5-yl; - the compounds of formula II in which R3 is an N-(methyl)tetrazol-5-yl; - the compounds of formula Ijyj in which R3 is a tetrazol-5-ylmethyl; 5 - the compounds of formula I]\j in which R3 is an N-(methyl) tetrazol-5-ylmethyl; - the compounds of formula iq in which R3 is a tetrazol-1 -ylmethyl or a tetrazol-2-ylmethyl; - the compounds of formula Ip in which R3 is a CH2NR6R7 group; the groups Alk, R6, R7 and Rg being as defined below for (I). 10 Preferred, among the compounds of formula (I), are compounds in which: Ri represents: . a phenyl, benzyl, benzhydryl, benzhydrylmethyl radical, in which each phenyl group is unsubstituted or substituted one or more times with substituents selected independently from a halogen atom, a hydroxyl, a (Ci-c4)alkyl, a (Ci-15 c4)alkoxy, a methylenedioxy, a cyano, a nitro, a trifluoromethyl, a difluoromethyl, a difluoromethoxy, a trifluoromethoxy, a trifluoromethylthio, a difluoromethylthio, an S(0)nAlk group, an 0S(0)nAlk group, a (Ci-c4)alkylcarbonyl group; . a furyl radical unsubstituted or substituted with one or more substituents selected 20 independently from a halogen atom, a (C]-c4)alkyl, a trifluoromethyl group; R2 represents a hydrogen atom or a (Ci-c4)alkylsulphonyl group; R3 represents a cyano, a hydroxyl, a (Ci-c4)alkoxy, a hydroxymethyl, a (Ci-COalkoxymethyl, a CONR^R? group, a COORg group, a tetrazol- 1-yl methyl or a tetrazol-2-ylmethyl, the groups R6, r7, Rg being as defined for (I); 25 - R4 represents a 4-chlorophenyl, a 4-methoxyphenyl or a 4-0S02-Alk, Alk representing a (Ci-c4)alkyl unsubstituted or substituted one or more times with a fluorine atom; - R5 represents a 2-chlorophenyl, a 2-bromophenyl or a 2,4-dichlorophenyl; or an acid addition salt, a hydrate, or a solvate thereof. 30 More particularly, the compounds of formula (I) are preferred in which: - Ri represents a 3-chlorophenyl, 3-fluorophenyl, 3,6-difluorophenyl, 2,6- difluorophenyl, 3-methoxyphenyl, 3-trifluoromethylphenyl, 3-trifluoromethoxyphenyl, a benzyl, a 4-trifluoromethylbenzyl or a 2-trifluoromethyl-4-methylfuryl group; 35 - R2 represents a hydrogen atom; - r3 represents a cyano, methoxy or dimethylaminocarbonyl group; 1253799-1 INTELLECTUAL property j office OF m.z 1 U DEC 2007 : RECEIVED! 10 - R4 represents a 4-chlorophenyl, a 4-methoxy or a 4-propanesulphonyloxy; - R5 represents a 2,4-dichlorophenyl or a 2-chlorophenyl; or an acid addition salt, a hydrate, or a solvate thereof. Quite particularly, the following compounds are preferred: 5 - N-{ [5-(4-chlorophenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1 //-pyrazol-3-yljmethyl} -3- cyanobenzenesulphonamide, - N-{[5-(4-chlorophenyl)-4-cyano-l-(2,4-dichlorophenyl)-1//-pyrazol-3-yljmethyl}-3- trifluorobenzenesulphonamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1 //-pyrazol-3 -yljmethyl} -2-10 trifluoromethoxybenzenesulphonamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1 //-pyrazol-3-yljmethyl} -3- methoxybenzenesulphonamide, -N-{[5-(4-chlorophenyl)-4-cyano-l-(2,4-dichlorophenyl)-l//-pyrazol-3-yl]methyl}-3-chlorobenzenesulphonamide, 15 - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2-chlorophenyl)-1 //-pyrazol-3-yl]methyl} -3- fluorobenzenesulphonamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2-chlorophenyl)-1 //-pyrazol-3-yl jmethyl} -2- fluorobenzenesulphonamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2-chlorophenyl)- l//-pyrazol-3-yljmethyl} -2-20 trifluoromethoxybenzenesulphonamide, - N- {[5 -(4-methoxyphenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1 //-pyrazol-3 - yl]methyl} -3.5-difluorobenzenesulphonamide, - N-{[5-(4-propanesulphonyloxyphenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1 //-pyrazol- 3 -y l]methyl} -3.5 - difluorobenzenesulphonamide, 25 - N- {[5-(4-chlorophenyl)-4-methoxy-1 -(2,4-dichlorophenyl)-1 //-pyrazol-3 - yljmethyl} -3-chlorobenzenesulphonamide, - 5-(4-chlorophenyl)-3-({[(3-chlorophenyl)sulphonyl]amino}methyl)-l-(2,4- dichlorophenyl)-iV-methy 1-1 //-pyrazole-4-carboxamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1 //-pyrazol-3-yl] methyl} -1 -30 phenylmethanesulphonamide, - N-{[5-(4-chlorophenyl)-4-cyano-l-(2,4-dichlorophenyl)-l//-pyrazol-3-yljmethyl}-5- methyl-2-(trifluoromethyl)furan-3 -sulphonamide; or an acid addition salt, a hydrate, or a solvate thereof. In accordance with the invention, the compounds of formula (I) can be prepared 35 according to a method which is characterized in that: a compound of formula: 1253799-1 INTELLECTUAL PROPERTY OFFICE OF N Z 11) DEC 2007 RF^E'VED 11 r .N R4 N (II) R. in which R2, r4, R5 are as defined for a compound of formula (I) and R'3 represents R3 or a precursor of r3, is reacted, in the presence of a base and in a solvent, with a sulphonyl halide of formula HalS02Ri, in which Ri is as defined for a compound of formula (I) and Hal represents a halogen atom. If applicable, the compound obtained of formula: in which R'3 is R3 or a precursor of r3, is converted to a compound of formula (I). Optionally, the compound of formula (I) is converted to one of its acid addition salts. The compounds of formula (I) in which R2 represents a (Cj-c3)alkyl can also be prepared from the corresponding compounds of formula (I) in which R2 represents a hydrogen atom by a method selected from the methods known by a person skilled in the art. Among the latter we may mention alkylation by an alkyl halide, reductive animation by an aldehyde in a reducing medium, or alternatively acylation by an acyl chloride, followed by a reduction. The compounds of formula (I) in which R2 represents a (C]-c4)alkylsulphonyl group can be prepared by substitution of the compounds of formula (I) in which R2 is a hydrogen atom, using methods known by a person skilled in the art. "Precursor of r3" means a group that can easily be converted to a substituent R3 according to the invention. According to the method of the present invention, the reaction of coupling of a compound of formula (II) with a sulphonyl halide is carried out in the presence of a base such as triethylamine or diisopropylethylamine, in a solvent such as dichloromethane or tetrahydrofuran, and at a temperature between room temperature and the reflux temperature of the solvent. (Ill) R. ■5 INTELLECTUAL property OFFICE of n.Z 1253799-1 1 u DEC 2007 d c o c 1 \/ c n 12 10 15 20 The compounds of formula (I) thus obtained can then be separated from the reaction mixture and purified by classical methods, for example by crystallization or chromatography. In the case of the compounds of formula (Ig), the group R'3, precursor of r3, represents a (tetrahydropyranyloxymethyl) -ch2othp group. The compound of formula: h CH.OTHP CHJ-N-SO-j-RJ (Illbis) obtained by the method according to the present invention is then hydrolysed in an acid medium to give a compound of formula (Ig) in which R3 is a hydroxymethyl. The compounds of formula (1^; R3 = (Ci-c4)alkoxy) can be used for obtaining the compounds of formula (iq; R3 = OH) by dealkylation, for example by the action of BBr3 or HBr. Using appropriate treatments, known by a person skilled in the art, the hydroxymethyl group is transformed to obtain the compounds of formula (Ij) to (Ijyj) in which R3 has various values. The compounds of formula (Ij^; R3 = tetrazolyl) and (Ijyj; R3 = tetrazolylmethyl) can also be prepared from the compounds of formula (1^; R3 = CN) and (id; R3 = CH2CN). The intermediates of formula (II) can be prepared in various ways depending on the value of the substituent r3. When R3 represents a cyano, the following reaction scheme is adopted: SCHEME 1 C02Alk KBH, al CH2OH 1253799-1 INTELLECTUAL PROPERTY OFFICE OF N Z IU DEC 200? 13 (V) q 5 "}/ if' 2 Phtalimide-K N CN pcl \ /CH,C1 W' .N m r"Xt-n cl 4 N R O r5 (VI) (VII) CN NH2NH2, H20/Me0H X ^CH2NH2 dl R, N >Y ■4 Rc (VIII) The compound of formula (IV) is prepared according to the method described in 5 patent application WO 2005/000820. Selective reduction of the ester function by kbh4 or LiAlH4 is carried out in stage al. The compound of formula (V) is halogenated, for example by pci5, in stage bl. The compound of formula (VI) thus obtained is then treated with potassium phthalimide, then, in stage dl, hydrazine hydrate is reacted in an alcohol to obtain the compound of formula (VIII) which 10 corresponds to the intermediate of formula (II) in which the substituent R3 is a cyano. When R3 represents a (Ci-c4)alkoxy, the following reaction scheme is followed for preparing the corresponding intermediate of formula (II). O O J, SCHEME 2 NaH/THF C /Cx EtO-C-R4 + Me-C-Me Me CH2 R4 a2 (IX) (X) OO OO Br, JL KOAc/AcOH c /Cx — Me CH R4 - Me CH R4 b2 I c2 Br OAc 15 (XI) (XII) 1253799-1 INTELLECTUAL propertv QFRCF OF ^ ? 1U DEC 200/ [Rb * ejv t- 14 HO. Me MeCOO\ .Me R5-NHNH2, HCl/AcOH v ^ ^ .Me meuuwv /T» + d2 r; "n'" r; y r5 r5 (XIII) (XIV) K2C03/Me0H/H20 (XIV) »- (xni) e2 K2C°3/DMF AlkOx Me AlkOx ^CH,Br Alkl f, if NBS (xni) J! ^ ^ , n R4 n' & R4 Y R5 R5 (XV) (XVI) 1) hexamethylenetetramine AlkOs\ ^CH,NH0 2) HC1 h2 Alk: C,-C4 Alk Ac : CHj-CO- (XVII) In stage a2, the arylbutane-l,3-dione derivative (X) is prepared by the action of acetone and of a hydride such as sodium hydride in THF on the ester R4C02Et. The compound of formula (XI) is obtained by bromination, followed by acetylation in stage c2 to form the compound of formula (XII). In stage d2, the action of the arylhydrazine hydrochloride leads to the mixture of compounds of formula (XIII) and (XIV). The compound of formula (XIV) is hydrolysed and is converted to a compound of formula (XIII). Then the compound of formula (XIII) is treated with a (C|-c4)alkyl halide of formula Alkl to form the compound of formula (XV). In stage g2, the action of N-bromosuccinimide (NBS) is used for preparing the compound of formula (XVI) then in stage h2, the action of hexamethylenetetramine is used to form the compound of formula (XVII) corresponding to the intermediate of formula (II) in which R3 is a (Ci-c4)alkoxy. 1253799-1 INTELLECTUAL PROPERTY OFFICE OF M.2 1 if DS-C 2007 H ft o E ? V E D 15 In stage g2, bromination can also lead to a dibrominated compound of formula (XVIII). Starting from this compound, a compound of formula (XVII) can be prepared in accordance with the following reaction scheme: SCHEME 3 10 15 AlkO\ ,CHBr2 /» R.-VN AlkO n I r5 (XVIII) DMSO a3 Vt /X /N N I R5 (XIX) CHO O NaBH4/MeOH b3 AlkOx R„ N CH2OH AlkO n I R5 (XX) c3 -N O (XXI) (XXI) nh2-nh2, h2o d3 (xvii) In stage a3, the dibrominated derivative of formula (XVIII) is treated with DMSO to obtain the aldehyde of formula (XIX) then, in stage b3, reduction by a metal hydride, for example sodium or potassium borohydride gives the compound of formula (XX). In stage c3, addition of the phthalimide is carried out in the presence of diethylazodicarboxylate (DEAD). The compound thus obtained of formula (XXI) is then treated with hydrazine hydrate to form the compound of formula (XVII). When R3 represents a cyanomethyl, (Ci-c4)alkoxymethyl, fluoromethyl or (Cj-c4)alkylthiomethyl group, the corresponding intermediates of formula (II) are prepared according to the reaction scheme shown below. 1253799-1 INTELLECTUAL PROPERTY OFFICE OF N Z 1 h rv r 7007 o 16 CH, C02Alk SCHEME 4 BrCH NBS R4 n r< a4 (XXII) XCH 2\ R4 N' r< u ,N .C02Alk reduction (XXIV) c4 2ViT X. /N C02Alk . xW r4 n r< b4 (xxiii) XCH 2YY -A /N ch2oh pcl r4 n Rc d4 (XXV) 10 15 XCH2\ /CH2C1 jh^ rXn n I R5 (XXVI) e4 XCH2YY R,Am'N ch2nh2 n R5 (xxvii) The compounds of formula (XXII) are described in patent EP 576 357. In stage a4, the methyl group of the compound of formula (XXII) is brominated by the action of NBS. In stage b4, the bromine is replaced with a nucleophilic group X selected from a fluorine atom, a cyano, a (Ci-c4)alkoxy, a (Ci-c4)alkylthio. Then the ester function is reduced with a reducing agent such as LiAlH4 or kbh4 to form the compound of formula (XXV). In stage d4, this compound is treated with an agent such as pci5 to give the compound of formula (XXVI). In stage e4, the successive action of potassium phthalimide and hydrazine or alternatively hexamethylene tetramine and hydrochloric acid leads to formation of the compound of formula (XXVIII) corresponding to a compound of formula (II) in which R2 is ch2x. When R3 represents a CHaSOAlk or CHiSC^Alk group, the corresponding intermediates of formula (II) are prepared from the intermediate of formula (XXIV) in which X = SAlk by a reaction of oxidation to obtain the intermediates of formula (XXIV) in which X = SOAlk or SO2AIL The oxidizing agent can be 1 u 1253799-1 17 metachloroperbenzoic acid or alternatively hydrogen peroxide. The intermediates of formula (XXIV) are then treated as in Scheme 4. For preparing the intermediate of formula (II) in which R'3 is a precursor of hydroxymethyl, i.e. a tetrahydropyranyloxymethyl group (ch2othp), the following reaction scheme is followed. SCHEME 5 Me, R„ VN 1 R5 (xxii) X02Alk BrCH. NBS a5 COjAlk OH- b5 (XXffl) hoch2 /CO2H M » rtV - hoch. AlkOH/H + n I R< c5 v R, N C02Alk "O' ch2othp (XXVIII) rap rX n I Rs (XXIX) d5 C02Alk ch2othp r' .N n LiAlH. e5 r ,ch2oh PClc n Rc f5 (xxx) ch2othp R t /N N I R5 (xxxii) ch2ci 1) Phtalimide 2) nh2-nh2 g5 (xxxi) ch2othp K4 N r5 (xxxiii) ce^nh,, /hostage a5 is carried out as described above for stage a4. In stage b5, substitution of bromine with the OH group and hydrolysis of the ester in a basic medium lead to the compound of formula (XXVIII). This compound is esterified in an acid medium to form the compound of formula (XXIX) then in stage d5, the hydroxyl group is protected with a group such as tetrahydropyranyl or fertbutoxymethyl. Then stages e5, f5 and g5 as described above for Scheme 1 are carried out for preparing the compound 1253799-1 INTELLECTUAL PROPERTY OFFICE OF M.Z 1 u DEC 2007 pprciv ED 18 of formula (XXXIII) corresponding to an intermediate of formula (II) in which R'3 is a tetrahydropyranyloxymethyl group. The method according to the invention is applied to the compound of formula (XXXIII) in order to prepare a compound of formula: CHLOTHP •ch2-nhs02r, f" r; yN r5 (XXXIV) To obtain a compound according to the invention of formula (I) in which R3 is a hydroxymethyl, the compound of formula (XXXIII) is treated in an acid medium, in an alcoholic solvent such as methanol. ch2oh From the compound thus obtained of formula: ,ch2-nhso2r, 11 , ^ -N R4 N' YiT' r5 (XXXV) a derivative of pyrazole-carboxylic acid of the following formula is prepared by oxidation: c02h ch2-nhso2r, r; Vn r> (XXXVI) Using methods known by a person skilled in the art, we can then prepare the compounds according to the invention of formula: 1253799-1 INTELLECTUAL PROPERTY OFRCF Or H7 1 u dec 200/ pprcivpp 19 10 co2r8 jt rA'n ch2-nhso2nhr, conr6r7 ch2_nhso2ri n R5 (xxxvii) (XXXVIII) Starting from a compound according to the invention of formula (XXXV) or (XXXX) in which R3 is a hydroxymethyl or a cyanomethyl, we can prepare a compound according to the invention of formula (I) in which R3 is a tetrazolylmethyl according to one of the following reaction schemes: SCHEME 6 ch2oh n: I ,N„ :N I ch2-nhso,r 2 1 tetrazole PPh3-DEAD ch, W ch2-nhso2r, rc (XXXV) (XXXIX) scheme 7 n: :n ch2cn ch2-nhso2r, Me3SiN3 Bu3SnO toluene / N ch, r; CHj-NHSOJRJ (XXXX) N I r5 (XXXXI) Starting from a compound according to the invention of formula (I) in which R3 represents a cyano, we can prepare a compound of formula (I) in which R3 represents a tetrazolyl by the action of tributyltin azide in a solvent such as xylene according to the following reaction scheme: 1253799-1 INTELLECTUAL PROPERTY office of m.z IU DEC 2007 RECEIVED 20 SCHEME 8 CN jpr CH2-NHS02R, \ ^CH2-NHS02R, Bu3SnN3 R4 N xylene (IA , R3 = CN) (iR, R3 = tetrazol-5-yl) r5 If applicable, a compound according to the invention of formula (I) in which R3 is an N-(methyl)tetrazolyl, or an N-(methyl)tetrazolylmethyl is prepared by aikylation of the tetrazole by an alkylating agent. When R3 represents a group -CH2NR6R7, the compound of formula (II) is prepared according to the following reaction scheme: SCHEME 9 O II HOCH C02Alk CH C02Alk rw - j 1 RTVN 39 r4 N' 1 I R5 R5 (xxix) (xxxxii) R6R7NCH2 co2Alk r6r7nh II b9 R: VN' C9 ^5 (xxxxiii) The oxidation in stage ag is carried out for example by the action of pyridinium chlorochromate according to J. Heterocyclic Chem. 1997, 34, 963. A reductive amination is carried out in stage bg. INTELLECTUAL PROPERTY j OFFICF OF N.Z j 1 u DEC 2007 ! RECEIVED 21 In stage eg, the compound obtained of formula (XXXXIV) is treated in accordance with stages e5, f5 and g5 described in scheme 5 to give the compound of formula (II). The following EXAMPLES describe the preparation of some compounds 5 according to the invention. These examples are not limiting and are only for illustrating the present invention. The numbers of the example compounds refer to those given in TABLES 1 and 2 below, which show the chemical structures and the physical properties of some compounds according to the invention. The following abbreviations are used in the Preparations and in the Examples: 10 ether: diethyl ether iso ether: diisopropyl ether DMSO: dimethylsulphoxide DMF: N,N-dimethylformamide THF: tetrahydrofuran 15 DCM: dichloromethane AcOEt: ethyl acetate MeOH: methanol EtOH: ethanol AcOH: acetic acid 20 DIPEA: diisopropylethylamine TFA: trifluoroacetic acid 2N Hydrochloric ether: 2N solution of hydrochloric acid in diethyl ether NBS: N-bromosuccinimide AIBN: 2,2'-Azobis(2-methylpropionitrile) 25 ppi13: triphenylphosphine DEAD: diethylazodicarboxylate PTSOH: paratoluene sulphonic acid BOP: benzotriazol-1 -yloxotris(dimethylamino)phosphonium hexafluorophosphate m.p.: melting point 30 RT: room temperature b.p.: boiling point HPLC: high-performance liquid chromatography Silica H: silica gel 60 H marketed by Merck (Darmstadt) Buffer solution pH = 2: solution of 16.66 g of khso4 and 32.32 g of k2so4 in 1 35 litre of water. 1253799-1 22 The proton nuclear magnetic resonance spectra ('H-NMR) are recorded at 200 MHz in DMSO-d6. The chemical shifts 8 are expressed in parts per million (ppm). The following abbreviations are used for interpreting the spectra: s: singlet, d: doublet, t: triplet, q: quadruplet, m: massive, mt: multiplet, bs: broad singlet, dd: doublet of doublets. The compounds according to the invention are analysed by the combination LC/UV/MS (liquid chromatography/UV detection/mass spectrometry). The molecular peak (MH+) and the retention time (tr) in minutes, are measured. Conditions A: Column used: Symmetry C18 of 2.1 x 50 mm, 3.5 |o.m, at 30°C, flow rate 0.4 ml/minute. The eluent has the following composition: - solvent A: 0.005 % of trifluoroacetic acid (TFA) in water at pH 3.15; - solvent B: 0.005 % of TFA in acetonitrile. Gradient: Time (min) % A % B 0 o o 0 10 10 90 15 10 90 16 100 0 20 o o 0 UV detection is performed at X = 210 nm and detection of mass in positive ESI (electrospray ionization) chemical ionization mode. Conditions MS2 Column used: XTERRA MS C18 of 2.1 x 30 mm, 3.5 jam, flow rate 0.8 ml/minute. The eluent has the following composition: Solvent A: 0.025 % of TFA in water. Solvent B: 0.025 % of TFA in acetonitrile. Gradient Time (min) % A % B 0 100 0 2 0 100 2.7 0 100 2.75 100 0 1253799-1 INTELLECTUAL PROPERTY OFFICE OF N '/ 1 U DEC 2007 RECEIVED UV detection is performed with an iodine array detector between 210 and 400 nm and detection of mass in positive ESI mode. Conditions MS5 These conditions of LC/MS analysis are similar to conditions MS2, with a flow rate of 1 ml/min. Preparation 1 3-(Aminomethyl)-1 -(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-1 //-pyrazole-4-carbonitrile hydrochloride. A) 1 -(2,4-Dichlorophenyl)-3 -hydroxymethyl-5 -(4-methoxyphenyl)-1 //-pyrazole-4- carbonitrile. A solution of 11.5 g of ethyl 4-cyano-l-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-l//-pyrazole-3-carboxylate (prepared according to patent application WO 2005/000820) in 150 ml of THF is prepared and 1.8 g of KBH4 and 1.5 g of LiCl are added, then it is stirred overnight at RT and it is heated under reflux for 2.5 hours. The reaction mixture is cooled to RT then filtered and washed with THF. The filtrate is evaporated to dryness then the residue is diluted with AcOEt and washed with water. The organic phase is dried over Na2S04, filtered and evaporated to dryness. The residue is triturated in pentane then filtered. 10 g of the expected compound is obtained. B) 3 -(Chloromethyl)-1 -(2,4-dichlorophenyl)-5 -(4-methoxyphenyl)-1 //-pyrazole-4- carbonitrile. 7.2 g of pci5 is added in small portions at 0°C to a solution of 10 g of the compound obtained in the preceding stage in 200 ml of DCM, and it is stirred for 20 minutes at 0°C then 24 hours at RT. The reaction mixture is poured onto water/ice mixture then the organic phase is separated and the aqueous phase is extracted again with DCM. The organic phases are combined and dried over Na2S04 then filtered and evaporated to dryness. The residue is triturated in pentane and 9.3 g of the expected compound is obtained. C) 1 -(2,4-Dichloromethyl)-3 -((1,3 -dioxo-1,3 -dihydro-2//-isoindol-2-yl)methyl)-5 - (4-methoxy)-1 //-pyrazole-4-carbonitrile. 5.3 g of potassium phthalimide and 3.5 g of Nal are added to 9.3 g of the compound obtained in the preceding stage in 100 ml of DMF and it is heated at 65°C for 2.5 hours. On returning to RT, the DMF is evaporated and then the residue is taken up in AcOEt and washed with an aqueous solution of IN NaOH. The organic phase is dried over Na2S04, filtered and evaporated to dryness. The residue is taken up in DCM, washed with an aqueous solution of IN NaOH then with saturated NaCl 1253799-1 24 solution. The organic phase is dried over Na2S04, filtered and evaporated to dryness to give the expected compound, (p = 10.53) D) 3-(Aminomethyl)-1 -(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-1 //-pyrazole-4- carbonitrile hydrochloride. 5 10.5 g of the phthalimide derivative obtained in the preceding stage is suspended in 250 ml of ethanol, 2.1 ml of hydrazine monohydrate is added and it is heated under reflux for 1 hour. The reaction mixture is filtered and then the organic phase is evaporated to dryness. The residue is taken up in ether and a solution of HC1 in hydrochloric ether is added. The precipitate that forms is filtered then rinsed with 10 pentane. 5 g of the expected compound is obtained, m.p. = 128°C. Preparation 2 1 -(5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-methoxy-1 //-pyrazol-3 -yl) methanamine. The LC/MS analyses are performed according to conditions A. 15 A) l-(4-Chlorophenyl)butane-l,3-dione. A mixture containing 45 g of ethyl 4-chlorobenzoate in 235 ml of anhydrous THF and 19.50 g of NaH (60% in mineral oil) in 235 ml of anhydrous THF is placed under nitrogen. 36 ml of acetone and 750 ml of additional anhydrous THF are added dropwise at 0°C, and it is heated under reflux for 3 hours. The mixture is acidified to 20 pH = 5 by addition of 2N HC1 then it is extracted with ether and washed with water and then with saturated NaHCC>3 solution; it is dried over MgS04 and concentrated. The raw product is dissolved in a minimum of toluene, the insoluble matter is filtered then it is purified by chromatography on silica, eluting with cyclohexane/AcOEt mixture (95/5; v/v). 47.9 g of the expected compound is obtained. 25 LC/MS: MH+ = 197.0; tr = 9.67 min. B) 2-Bromo-1 -(4-chlorophenyl)butane-1,3-dione. 15.35 g of the compound from the preceding stage in 20 ml of DCM is placed under nitrogen and 4.04 ml of bromine is added dropwise at 0°C. At the end of addition, it is evaporated to dryness then 300 ml of DCM is added; it is washed with 30 water, dried over Na2SC>4 then filtered and evaporated to dryness. 21.15 g of the expected compound is obtained. C) l-(4-Chlorobenzoyl)-2-oxopropyl acetate. 16.74 g of potassium acetate dissolved in 76.76 ml of hot acetic acid is placed under nitrogen. 21.5 g of the bromine derivative obtained in the preceding stage is 35 added, in portions, at 100°C, and it is heated at 120°C for 3 hours. The reaction mixture is poured into 1 litre of water and it is extracted with 500 ml of ether. The 1253799-1 INTELLECTUAL PROPERTV OFFICE OF N.2 1 u DEC 2007 RECEIVED ether phase is washed twice with 250 ml of saturated NaHCC>3 solution then it is dried over Na2S04, filtered and evaporated to dryness. 16.28 g of the expected compound is obtained. LC/MS: MH+ - 255.0; tr = 8.42 min. D) 5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-3-methyl-l//-pyrazol-4-yl acetate. A mixture containing 16.23 g of the compound from the preceding stage and 13.92 g of (2,4-dichlorophenyl)hydrazine hydrochloride is heated under reflux for 3 hours. On returning to RT, 400 ml of water is added then the organic phase is washed with saturated NaHC03 solution, then with water, and then dried over Na2S04. It is filtered and evaporated to dryness. The product obtained is purified by chromatography on silica, eluting with a DCM/MeOH mixture (98/2; v/v). 5.80 g of the expected compound (LC/MS: MH = 395.0; tr = 10.80 min) and 4.63 g of the deacetylated compound identical to that prepared in the next stage are obtained. E) 5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-3-methyl-l//-pyrazol-4-ol. 16.2 g of the compound obtained in the preceding stage in 82 ml of methanol is mixed with 7.1 g of potassium carbonate in solution in water (v/v) and it is stirred for 4 hours at RT. The reaction mixture is concentrated and then diluted by adding 500 ml of water and it is extracted with 500 ml of DCM. The organic phase is washed with a buffer solution at pH = 2 of distilled water, then dried over Na2S04, filtered and evaporated to dryness. 11.56 g of the expected compound is obtained. LC/MS: MH+ 355.0 , tr = 9.69 min. F) 5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methoxy-3-methyl-l//-pyrazole. 16.25 g of the compound obtained in the preceding stage dissolved in 200 ml of DMF is placed under nitrogen, 7.05 g of K2CO3 and 7.21 g of ch3i are added, then it is heated at 60°C under nitrogen, stirring for 3 hours. On returning to RT, the reaction mixture is filtered. 100 ml of water is added to the filtrate and it is extracted with 100 ml of DCM (twice). The organic phase is washed with 100 ml of water (5 times) then dried over Na2S04, filtered and concentrated to dryness. The residue is purified on a silica column. 9.07 g of the expected compound is obtained. LC/MS: MH+ = 367.0; tr = 11.10 min. G) 3-Bromomethyl-5-(4-chlorophenyl)-1 -(2,4-dichlorophenyl)-4-methoxy-1H-pyrazole. 9.07 g of the compound obtained in the preceding stage in 125 ml of cci4 is placed under nitrogen and 4.87 g of NBS, 0.79 g of benzoyl peroxide and 0.1 g of AIBN are added, then it is heated under reflux for 60 hours. On returning to RT, it is filtered on Celite and evaporated to dryness, then it is purified by chromatography on 1253799-1 26 10 15 20 • 25 30 silica, eluting with cyclohexane/AcOEt (95/5; v/v). Besides the monobromine compound expected (2.67 g), 3,3-dibromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methoxy-l//-pyrazole is obtained (5 g). LC/MS: MH+ = 446.8; tr = 11.67 min. LC/MS: MH+ - 524.8; tr = 12.06 min. H) 1 -(5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-methoxy-1 //-pyrazol-3-yl) methanamine. A mixture containing 2.65 g of the monobromine compound obtained in the preceding stage, 2.52 g of hexamethylene tetramine and 0.90 g of Nal in 50 ml of EtOH is placed under nitrogen. It is stirred at RT for 18 hours, then 10 ml of concentrated HCl and 12 ml of ethanol are added and it is heated under reflux for 12 hours. On returning to RT, the mixture is filtered then the filtrate is evaporated to dryness and then taken up in DCM. The organic phase is extracted with 100 ml of 10% HCl. The aqueous phase is washed with DCM then basified and extracted with DCM. The organic phase is dried over Na2S04, filtered and evaporated to dryness. The residue is purified on silica, eluting with DCM/MeOH (93/7; v/v). 1.47 g of the expected compound is obtained. LC/MS: MH+ = 382.0; tr = 6.83 min. I) 5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-methoxy-1 //-pyrazole-3-carbaldehyde. Under nitrogen, 5 g of the 3,3-dibromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methoxy-1 //-pyrazole obtained in stage G is placed in 30 ml of DMSO, and it is heated at 120°C for 6 hours. The reaction mixture is poured into 100 ml of water and it is extracted twice with 100 ml of AcOEt. The organic phase is washed with 100 ml of saturated NaCl and then dried over Na2S04. After evaporating to dryness, 4 g of the unpurified expected compound is obtained. LC/MS: MH+ = 381.0; tr =11.06 min. J) (5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-methoxy-l //-pyrazol-3-yl) methanol. 4 g of the compound obtained in the preceding stage is placed in 104 ml of methanol and 0.99 g of NaBH4 is added at 0°C, and it is stirred at 0°C for 45 minutes. 3 ml of AcOH is added to decompose excess NaBH4. It is evaporated to dryness then the residue is taken up in 100 ml of DCM, it is washed with 100 ml of saturated NaHC03 solution (twice) then the organic phase is dried and it is concentrated to dryness. 3.6 g of the unpurified expected compound is obtained. LC/MS: MH+ = 383.0; tr = 9.68 min. 1253799-1 INTELLECTUAL property OFFICE of N.Z 1 u DEC 200? RECEIVED. 27 K) 2-((5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methoxy-l//-pyrazol-3-yl) methyl)-1 //-isoindole-1,3 -(2//)-dione. 3.6 g of the compound obtained in the preceding stage, 2.46 g of ppi13 and 1.38 g of phthalimide in solution in 156 ml of THF are mixed together. 1.63 g of DEAD is 5 added dropwise at -10°C, and it is left overnight at RT. The reaction mixture is treated with 100 ml of a buffer solution to pH = 2; the organic phase is diluted with 200 ml of ether then it is washed with 100 ml of saturated NaHCC>3 solution and then 100 ml of saturated NaCl solution; it is dried over Na2S04, filtered and evaporated to dryness. The product obtained is purified on silica, eluting with a DCM/MeOH mixture (98/2; 10 v/v). 3.4 g of the expected compound is obtained. LC/MS: MH+ = 512.0; tr - 11.43 min. L) 1 -(5 -(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-methoxy-1 //-pyrazol-3-yl) methanamine. 3.4 g of the compound obtained in the preceding stage and 0.67 g of hydrazine 15 monohydrate in solution in 95 ml of methanol are placed under nitrogen, and heated under reflux for 3 hours. The reaction mixture is evaporated to dryness, the residue is taken up in 150 ml of ether; the organic phase is washed with 10% NaOH solution then with saturated NaHC03 solution and then with saturated NaCl solution. It is extracted with DCM and then evaporated to dryness. 2.45 g of the expected 20 compound, identical to that obtained in stage H, is obtained. Preparation 3 1 -(5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-(tetrahydro-2//-pyran-2-yloxymethyl)-1 //-pyrazol- 3-yl)methanamine. A) Methyl 4-(bromomethyl)-5-(4-chlorophenyl)-1 -(2,4-dichlorophenyl)-1H-25 pyrazole-3-carboxylate. 19 g of methyl 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-l//-pyrazole-3-carboxylate is placed in 200 ml of cci4 and 8.54 g of NBS and then 1 g of benzoyl peroxide are added, heating under reflux overnight. On returning to RT, the precipitate that forms is filtered and washed with cci4. All of the filtrate is evaporated, then 30 taken up in AcOEt and washed with saturated NaCl solution (twice). It is dried over MgS04 and evaporated. The expected compound crystallizes in iso ether, it is filtered and dried to obtain 19.4 g of the expected compound. B) 5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-hydroxymethyl- l//-pyrazole-3-carboxylic acid. 35 17 g of the compound obtained in the preceding stage and 1.5 g of LiOH, H2O are placed in 100 ml of THF and 50 ml of water and heated for 3 hours and then stirred 1253799-1 INTELLECTUAL PROPERTY OFFICE OF 1 u DEC 2007 RECEIVED 28 overnight at RT. The precipitate that forms is filtered and then the filtrate is evaporated. The residue is taken up in AcOEt then washed with saturated NaCl solution. It is dried over MgS04, filtered, and the filtrate is concentrated to obtain 11 g of the expected compound. 5 C) Methyl 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-hydroxymethyl-l//- pyrazole-3-carboxylate. 10 g of the acid formed in the preceding stage is dissolved in 100 ml of MeOH, 1 ml of concentrated H2SO4 is added and heated under reflux for 2 hours. After cooling, and evaporating the solvent, it is taken up in AcOEt. It is washed with 10 NaHC03 solution then with saturated NaCl solution and it is dried over MgS04. It is purified by chromatography, eluting with AcOEt/cyclohexane mixture (10/90 then 20/80; v/v). 2.8 g of the expected compound which crystallizes with iso ether is obtained. D) Methyl 5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-(tetrahydro-2//-pyran-2-15 yloxymethyl)-1 //-pyrazole-3 -carboxylate. 2.8 g of the compound obtained in the preceding stage is dissolved in 48 ml of DCM, 0.68 g of 3,4-dihydro-2//-pyrane and 0.07 g of PTSOH are added, then it is stirred at RT for 1 hour. The reaction mixture is washed with a solution of NaHC03 then with saturated NaCl solution. It is dried over MgS04 and evaporated. The 20 product obtained is purified by chromatography on silica, eluting with AcOEt/cyclohexane mixture (5/95 then 90/10; v/v). The expected compound crystallizes in cyclohexane/AcOEt. 2.2 g is obtained. E) 2-(5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-(tetrahydro-2//-pyran-2-yloxymethyl)-l//-pyrazol-3-yl)methyl)-1.3-bis(methylene)isoindoline. 25 2.6 g of the compound obtained in the preceding stage, 0.97 g of phthalimide then 1.74 g of ppi13 are dissolved in 50.5 ml of THF and 1.16 g of DEAD is added dropwise at -10°C. It is allowed to return to RT then it is stirred at RT for 96 hours. It is extracted with ether and washed with saturated NaCl solution, then it is dried over MgS04 and evaporated. The product obtained is purified by chromatography on silica, 30 eluting with AcOEt/cyclohexane (5/95; v/v). 2.2 g of the expected compound is obtained. F) 1 -(5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-(tetrahydro-2//-pyran-2-yloxymethyl)-1 //-pyrazol-3 -yl)methanamine. 2.2 g of the compound obtained in the preceding stage is placed in 40 ml of 35 MeOH, 0.40 ml of hydrazine hydrate is added and it is heated under reflux for 1.5 h. It is left to cool, the solvent is evaporated and it is taken up in DCM. It is washed with INTELLECTUAL PROPERTY OFFICE OF N 2. IU DEC 2007 .RECEIVED 29 10% NaOH solution then with saturated NaCl solution, it is dried over MgS04 and evaporated. 1.57 g of the expected compound in the raw form is obtained. Preparation 4 1 -(5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-(methoxymethyl)-1 //-pyrazol-3-yl)methanamine. A) Methyl 5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-l//-pyrazole-3-carboxylate. 20 g of l-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl)-l//-pyrazole-3-carboxylic acid is placed in 200 ml of MeOH, 0.5 g of toluene sulphonyl chloride is added and it is heated under reflux overnight. It is evaporated to half, then the precipitate that forms is filtered. It is washed with ether and then dried, obtaining 20.6 g of the expected compound. B) Methyl 4-(Bromophenyl)-5-(4-chlorophenyl)-1 -(2,4-dichlorophenyl)-4-(bromomethyl)-1 //-pyrazole-3 -carboxylate. 16.5 g of the compound obtained in the preceding stage is placed in 200 ml of cci4, 7.42 g of NBS and 0.1 g of benzoyl peroxide are added then it is heated under reflux overnight. The precipitate that forms is filtered and then washed with cci4. After evaporating the solvent it is taken up in DCM, then the organic phase is washed with water and then with saturated NaCl solution. It is dried over MgS04 and evaporated. The expected compound is crystallized with DCM and iso ether. 1.3 g of the expected compound is obtained. C) Methyl 5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-(methoxyphenyl)-1H-pyrazole-3 -carboxylate. 2.5 g of sodium is washed with 100 ml of toluene and then 100 ml of ether, then it is cut into small pieces and placed in 500 ml of MeOH. 13 g of the bromine derivative obtained in the preceding stage is added to the solution of sodium methylate thus prepared and it is stirred for 30 minutes, leaving the reaction mixture at RT for 72 hours. The precipitate that forms is filtered then the filtrate is evaporated. It is treated with 25% HCl, and taken up in AcOEt. After decanting, the organic phase is washed with saturated NaCl solution (twice). It is dried over Na2S04 and concentrated. The expected product crystallizes in iso ether. 1 g of the expected compound is obtained. D) 5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methoxyphenyl-l//-pyrazol-3-yl)methanol. 5.8 g of the compound obtained in the preceding stage is dissolved in 100 ml of THF and 0.82 g of LiAlH4 is added in small portions at 0°C. It is stirred at RT for 30 INTELLECTUAL PROPERTY" OFFICE or Hz J 0 DEC 2007 1253799-1 RF^cnfCi 30 minutes and then hydrolysed by adding 15 ml of IN NaOH solution. The precipitate that forms is filtered then washed with THF and the filtrate is evaporated. It is taken up in AcOEt and washed with saturated NaCl solution. It is dried over MgS04 and evaporated. It is crystallized in AcOEt/iso ether. 4.6 g of the expected compound is 5 obtained. E) 3-(Chloromethyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methoxymethyl- l//-pyrazole. 4.5 g of the compound obtained in the preceding stage is dissolved in 50 ml of DCM, then 2.6 g of pci5 is added in small portions at 0°C and it is stirred at RT for 1 10 hour. 25 ml of water is added and it is left overnight at RT. After decanting, the organic phase is washed with saturated NaCl solution (twice), then it is dried over Na2S04 and evaporated. It is chromatographed on silica, eluting with AcOEt/cyclohexane mixture (10/90; v/v). 2.17 g of the expected compound and 2 g of the equivalent compound bearing the dichloromethyl substituent in position 3 are 15 obtained. F) 1 -(5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-(methoxymethyl)-1 //-pyrazol-3- yl)methanamine. 2 g of the compound obtained in the preceding stage is dissolved in 50 ml of chloroform and 0.80 g of hexamethylenetetramine is added, then it is stirred for 20 several days at RT. It is evaporated to half, and 50 ml of ether is added. The precipitate that forms is filtered then it is taken up in 100 ml of EtOH and 15 ml of concentrated KC1. It is heated under reflux for 2 hours and then left overnight at RT. The precipitate of nh4ci that forms is filtered. The filtrate is evaporated, it is taken up in DCM then washed with a solution of NaHC03 and then with saturated NaCl 25 solution (twice). It is dried over MgS04 and evaporated. It is taken up in iso ether. It is evaporated again, obtaining 1.7 g of the expected compound. NMR: 7.1: d: 2H; 7.45: d: 2H; 7.55: dd: 1 H; 7.6: d: 1 H; 7.75: d: 1 H. EXAMPLE 1: Compound No. 52 3 -Chloro-N-((5 -(4-chlorophenyl)-1 -(2,4-dichlorophenyl)-4-methoxy-1 //-pyrazol-30 3 -yl)methyl)benzenesulphonamide. 0.32 g of the compound obtained in Preparation 2 is mixed with 0.09 g of triethylamine and 0.19 g of 3-chlorobenzenesulphonyl in 20 ml of dichloromethane and is stirred for one hour at RT. It is diluted with 100 ml of DCM then washed with 10% HCl solution, then with 25% NaOH solution, then with saturated NaCl solution 35 and it is extracted with DCM. It is dried, filtered and evaporated to dryness. The 1253799-1 INTELLECTUAL PROPERTY OFFICE OF M.2 11) DEC 2007 rfc = nfpo 31 10 15 20 • 25 30 residue is purified by chromatography on silica, eluting with DCM/MeOH mixture (96/4; v/v). 0.21 g of the expected compound is obtained. EXAMPLE 2: Compound No. 53 3-Chloro-N-((5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-hydroxymethyl-l//-pyrazol-3-yl)methyl)benzenesulphonamide. A) 3-Chloro-N-((5-(4-chlorophenyl)-1 -((tetrahydro-2//-pyran-2-yloxy)methyl)-1H-pyrazol-3-yl)methyl)benzenesulphonamide. Starting from 0.7 g of the compound obtained in Preparation 3, 0.35g of 3-chlorobenzenesulphonyl and 0.33 g of triethylamine, 0.847 g of the expected compound is obtained by following the procedure described in the preceding example. B) 3-Chloro-N-((5-(4-chlorophenyl)-4-(hydroxymethyl)-1H-pyrazol-3-yl)methyl)benzenesulphonamide. 0.847 g of the compound obtained in the preceding stage is dissolved in 40 ml of MeOH. 1 ml of concentrated HCl is added and it is heated under reflux for 10 minutes. It is left to cool, then the solvent is evaporated and the residue is taken up in AcOEt. It is washed with saturated NaCl solution (twice), then dried over MgS04 and evaporated. The product obtained is purified by chromatography, eluting with AcOEt/cyclohexane mixture (10/90 then 20/80 then 25/75; v/v). 176 mg of the expected compound and 289 mg of the corresponding compound of formula (I) in which R-3 is a methoxymethyl group are obtained. EXAMPLE 3: Compound No. 48 3-Chloro-N-((5-(4-Chlorophenyl)-1 -(2,4-dichlorophenyl)-4-(methoxymethyl)-l//-pyrazol-3-yl)-methyl)benzenesulphonamide. 0.45 g of amine obtained in Preparation 4 is placed in 20 ml of DCM. 0.26 g of 3-chlorobenzenesulphonyl and 0.25 g of triethylamine are added, then it is stirred for 3 hours at RT. 15 ml of water is added, and it is stirred for 10 minutes. After decanting, the organic phase is washed with NaHC0s/KHS04 solution then with saturated NaCl solution (twice). It is dried over MgS04 and evaporated. It is taken up in iso ether and is then purified by chromatography on silica, eluting with AcOEt/cyclohexane (5/95; v/v). 0.230 g of the expected compound is obtained, m.p. = 154°C. EXAMPLE 4: Compound No. 55 5-(4-Chlorophenyl)-3-((((3-chlorophenyl)sulphonyl)amino)methyl)-l-(2,4-dichlorophenyl)-N,N-dimethyl-l//-pyrazole-4-carboxamide. A) 5-(4-chlorophenyl)-3-((((3-chlorophenyl)sulphonyl)amino)methyl)-l-(2,4-dichlorophenyl)-1 //-pyrazole-4-carboxylic acid. 1253799-1 INTELLECTUAL PROPERTY OFFICF OF N.2 1 y DEC 2007 P fur: ^ " r: 9 j 32 13.36 g of Cr2C>3 is added to a mixture of 11.5 ml of concentrated H2SO4 solution, diluted in 50 ml of cold water to prepare the Jones reagent. 0.5 g of the compound from Example 2 is dissolved in 15 ml of acetone then 5 ml of the Jones reagent is added slowly at a temperature between 0°C and 5°C. It is stirred for 2 days. 5 10 ml of isopropanol is added to destroy the excess reagent, and the precipitate that forms is filtered. The filtrate is extracted with 30 ml of ether. The organic phase is washed with saturated NaCl solution (twice), and then dried over MgSC>4. It is evaporated and taken up in hot iso ether. The expected compound crystallizes. 440 mg is obtained, m.p. = 211°C. 10 B) 5-(4-Chlorophenyl)-3-((((3-chlorophenyl)sulphonyl)amino)methyl)-1 -(2,4- dichlorophenyl)-N,N-dimethyl-l//-pyrazole-4-carboxamide. 0.4 g of acid obtained in the preceding stage is dissolved in 20 ml of DCM, 0.37 g of BOP and 0.05 g of methylamine are added and it is stirred overnight at RT. 10 ml of water is added, then the organic phase is decanted. After evaporating, the residue is 15 taken up in AcOEt. It is washed successively with solutions of k2so4, NaHC03 and NaCl (saturated solution), it is dried over MgS04 and evaporated to dryness. The residue is taken up in hot Et20, then crystallized. 0.35 g of the expected compound is obtained, m.p. = 178°C. EXAMPLE 5: Compound No. 57 20 0.69 g of the compound from Example 1 is placed in 15 ml of DCM, 12.36 mg of BBr3 is added at -20°C then it is stirred for 1 hour at -20°C then 3 hours at RT. 100 ml of water and 100 ml of DCM are added to the reaction mixture, it is decanted, then the organic phase is washed with 100 ml of dilute HCl; it is dried over MgS04 and evaporated to dryness. The residue is taken up in 100 ml of DCM. The expected 25 compound precipitates, and 373 mg of the expected product is obtained. LC/MS: MH+ = 541.8; tr = 10.69 min. EXAMPLE 6: The compounds of formula (Ia) described in Table 1 are prepared either according to the methods described above, or by combinatorial chemistry according to 30 the method described below. The pyrazole-methylamine derivative of formula (II) is dissolved in DMF at a concentration of 0.1M in the presence of 3 equivalents of DIPEA. 300 jj.1 of this solution is placed in each 2-ml well, and 120 ju.1 of solution of sulphonyl chloride (r1so2ci) at a concentration of 0.25M in THF is added. The plates are agitated at RT 35 for 16 hours, then evaporated. The products that form are dissolved in each well with 500 jliI of AcOEt, 400 pi of 0.1 M Na2C03 is added and the plates are agitated. After INTELLECTUAL property qfficf OF m 7 1 U dec 200; 33 decanting, 350 jal of aqueous phase is removed then 40 jj.1 of DMF and then 300 j_il of CH3CN are added. EXAMPLE 7: Compound No. 45 N-((4-cyano-l-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-l//-pyrazol-3-5 yl)methyl)-2,6-difluorobenzenesulphonamide. 0.98 ml of triethylamine and 0.75 g of 2,6-difluorobenzenesulphonyl chloride in solution in DCM are added to a solution containing 1.2 g of the compound from Preparation 1. After stirring overnight at RT, the DCM is concentrated, the residue is taken up in AcOEt, the organic phase is washed with buffer solution pH2, then with 10 saturated NaHCOs solution and then with saturated NaCl solution; it is dried over MgS04 and concentrated to dryness under vacuum. It is purified by chromatography on silica, eluting with cyclohexane/AcOEt mixture (90/10; v/v). 1.5 g of the expected compound is obtained, m.p. = 170°C. EXAMPLE 8: Compound No. 72 15 N-((4-cyano-l-(2,4-dichlorophenyl)-5-(4-hydroxyphenyl)-l//-pyrazol-3- yl)methyl)-2,6-difluorobenzenesulphonamide. 1 g of the compound obtained in the preceding example is placed in 15 ml of DCM. 4.56 g of BBr3 in 1M solution in DCM is introduced dropwise at -20°C, under nitrogen, it is stirred for 1 hour at -20°C, then the temperature is allowed to rise. After 20 72 hours at RT, the reaction mixture is poured into a water/ice/DCM mixture; the organic phase is washed with 30 ml of saturated NaHC03 solution, 30 ml of buffer solution pH2, then 2 x 30 ml of saturated NaCl solution. It is decanted and dried under vacuum, obtaining 0.782 g of the expected compound, m.p. = 196°C. EXAMPLE 9: Compound No. 73 25 N-((4-cyano)-l-(2,4-dichlorophenyl)-5-(4-((propylsulphonyl)oxy)phenyl)-l//- pyrazol-3-yl)methyl)-2,6-difluorobenzenesulphonamide. A solution is prepared containing 0.35 g of the compound from the preceding example in 20 ml of DCM, and 1.44 ml of NEt3 and then 0.103 g of n-propanesulphonyl chloride are added. After stirring for 1.5 h at RT, 10 ml of water is 30 added, then it is decanted and the organic phase is washed with 15 ml of saturated NaCl solution. After removing the solvents, it is purified by chromatography on silica, eluting with cyclohexane/AcOEt mixture (90/10 to 70/30; v/v). 0.144 mg of the expected compound is obtained, m.p. = 77°C. The following tables show the chemical structures and physical properties of 35 some compounds according to the invention. 1253799-1 INTELLECTUAL PROPERTY OFFICE OF MZ 1 u DtC 2007 r" P" i * j r- ph 34 In these tables, Me and tBu represent the methyl and /erZ-butyl groups, respectively. TABLE 1 Compounds r4, r*4 f5, r'5 R. Characterization Conditions m.p. °C 1 4-C1 2,4-diCl MH+ = 534.8 tr = 2.00 MS5 2 4-C1 2,4-diCl -O F MH+ = 552.7 tr = 2.04 MS5 3 4-C1 2,4-diCl -r s MH+ = 522.7 tr = 2.01 MS5 m.p. = 184 4 4-C1 2,4-diCl Me -Vt Me MH+ = 544.8 tr = 2.13 MS5 5 4-C1 2,4-diCl MH+ = 552.7 tr = 2.08 MS5 6 4-C1 2,4-diCl .CN ■o OO O +» 7 s 1253799-1 INTELLECTUAL PROPERTY OFFICE OF M.Z 10 DEC 2007 35 Compounds r4, r'4 r5, r'5 Ri Characterization Conditions m.p. °C MS5 m.p. = 167 7 4-C1 2,4-diCl —^ ^—cn MH+ = 541.8 tr = 1.99 MS5 m.p. = 187 8 4-C1 2,4-diCl ocf3 MH+ = 600.7 tr = 2.12 MS5 m.p. = 126 9 4-C1 2,4-diCl O MH+ = 534.8 tr = 2.03 MS5 10 4-C1 2,4-diCl f MH+ = 534.8 tr = 2.07 MS5 11 4-C1 2,4-diCl CF3 MH+ = 584.7 tr = 2.09 MS5 m.p. = 104 12 4-C1 2,4-diCl OMe MH+ = 546.8 tr = 2.07 MS5 m.p. = 141 13 4-C1 2,4-diCl Me 5-° CF3 MH+ = 588.7 tr = 2.14 MS5 m.p. = 184 14 4-C1 2,4-diCl -CH2-^ ^CF, MH+ = 598.8 tr = 2.11 MS5 m.p. = 152 INTELLECTUAL PROPERTY OFFICE OF N.Z 1 U OEC 2007 received 36 Compounds r4, r'4 rs, r'5 R. Characterization Conditions m.p. °C 15 4-C1 2,4-diCl 'ch2_hv3 ncf3 MH+ = 598.8 tr = 2.13 MS5 m.p. = 89 16 4-C1 2,4-diCl ci cK MH+ = 584.7 tr = 2.13 MS5 m.p. = 165 17 4-C1 2,4-diCl -CHr^\L) MH+ = 530.8 tr = 2.08 MS5 m.p. = 93 18 4-C1 2,4-diCl -r~ s~"S. MH+ = 556.7 tr = 2.13 MS5 19 4-C1 2,4-diCl CI MH+ = 550.7 tr = 2.11 MS5 m.p. = 98 20 4-C1 2,4-diCl F ^C1 MH+ = 568.7 tr = 2.10 MS5 21 4-C1 2,4-diCl cf3 MH+ = 584.7 tr = 2.10 MS5 22 4-C1 2-C1 ~Q OMe MH+ = 513.5 tr = 1.82 MS5 INTELLECTUAL PROPERTY OFPICF OF N.Z 1« DEC 2007 IRFfHPi v p n 37 Compounds r4, r'4 f5, r'5 Ri Characterization Conditions m.p. °C 23 4-C1 2-C1 o. f MH+ = 501.5 tr = 1.83 MS2 m.p. = 85 24 4-C1 2-C1 ■C»,-0 MH+ = 497.5 tr = 1.83 MS2 25 4-C1 2-C1 CS V CI MH+ = 551.4 tr= 1.90 MS2 m.p. = 110 26 4-C1 2-C1 ^ ^—OMe MH+ = 513.5 tr = 1.80 MS2 27 4-C1 2-C1 -0 cf3 MH+ = 551.5 tr = 1.86 MS2 28 4-C1 2-C1 -o MH+ = 517.4 tr = 1.87 MS2 29 4-C1 2-C1 s— ^C1 MH+ = 523.4 tr = 1.87 MS2 m.p. = 118 30 4-C1 2-C1 ^Me Me MH+ = 511.5 tr = 1.89 MS2 m.p. = 154 31 4-C1 2-C1 MH+ = 533.5 tr = 1.88 MS2 1253799-1 INTELLECTUAL property ofpicf of nj? 1 y DEC 200/ RECEIVED 38 Compounds r4, r'4 rs, r'5 Ri Characterization Conditions m.p. °C 32 4-C1 2-C1 tBu MH+ = 539.5 tr= 1.96 MS2 33 4-C1 2-C1 MH+ = 501.5 tr = 1.81 MS2 m.p. = 75 34 4-C1 2-C1 MH+ = 497.5 tr = 1.84 MS2 35 4-C1 2-C1 -O-' MH+ = 501.5 tr= 1.82 MS2 36 4-C1 2-C1 -0 ocf3 MH+ = 567.5 tr= 1.88 MS2 m.p. = 87 37 4-C1 2-C1 ^)—Me ^C1 MH+ = 531.5 tr = 1.90 MS2 38 4-C1 2-C1 OMe OMe MH+ = 543.5 tr = 1.81 MS2 39 4-C1 2-C1 Me. -i " > n Me MH+ = 502.5 tr = 1.80 MS2 40 4-C1 2-C1 MH+ = 525.5 tr = 1.81 MS2 intellectual PR0PFRTV officf OF 1 0 DcC 2007 R.E C EIV E D 39 Compounds r4, r'4 rs, r'5 Ri Characterization Conditions m.p. °C 41 4-C1 2-C1 -r s— MH+ = 489.4 tr = 1.80 MS2 42 4-C1 2-C1 ft ^ ^-NMe2 MH+ = 576.5 tr= 1.84 MS2 43 4-C1 2-C1 COMe MH+ - 525.5 tr = 1.78 MS5 m.p. = 117 44 4-OMe 2,4-diCl O F MH+ = 548.8 tr = 6.67 MS 5 m.p. = 153 45 4-OMe 2,4-diCl F MH+ = 548.8 tr = 6.39 MS5 m.p. = 170 46 4-OMe 2,4-diCl "Q, MH+ = 537.8 tr = 6.35 MS5 47 4-OMe 2,4-diCl D cf3 MH+ = 580.8 tr = 6.80 MS5 1253799-1 INTELLECTUAL propertv OFFICE OF M.Z 11) DEC 2007 RECEIVED 40 TABLE 2 Compounds ri r3 Characterization Conditions m.p. °C 48 -Q CI -CH2OMe m.p. = 154°C 49 ■c.,-0 ^CF3 -CH2OMe m.p. = 74°C 50 -CH2OMe m.p. = 143°C 51 0 ii ^C-Me -O -CH2OMe m.p. = 85°C 52 -Q CI -OMe MH+ = 556.0 tr= 11.48 53 CI -CH2OH m.p. = 83°C 1253799-1 INTELLECTUAL property OFFICE OF M.Z. 1 o 0 EC 2007 received 41 Compounds r, rs Characterization Conditions m.p. °C 54 cf3 -CH2OH m.p. = 82°C 55 -Q CI 0 ii -C-NHMe m.p. = 178°C 56 -Q CI 0 ii -C-NMe2 m.p. = 164°C 57 -Q CI -OH MH+ = 541.8 tr = 10.69 58 -Q ci 0 ii -C-OMe m.p. = 132°C 59 -Q CI -CH2OEt m.p. = 143°C 60 ■ch.-XQ ^CF3 0 ii -C-NHMe m.p. = 98°C 61 "CF3 0 ii -C-NMe2 m.p. = 83°C 62 ^-O ^CF3 0 ii C-OMe m.p. = 125°C 63 CI -CH2CN 1253799-1 INTELLECTUAL PROPERTV OFFICE OF M 2 1 y DEC 2007 RECEIVED 42 Compounds ri r3 Characterization Conditions m.p. °C 64 -Q CI N— -chrf N— H \[ SJ 65 o CI N— -CH2-1 N—' Me V S[ 66 ■Q CI N -CH.-N 2 \ N= et N= -CH,—N 2 v— N N N Mixture of isomers MH+ = 607 trj = 10.52 tr2 = 10.99 67 CI N—N N—N H 68 CI N=N N=N TABLE 3 CH2-N-S02-RJ R„ (IA) 1253799-1 43 Compounds r4, r'4 rs, r'5 r. r2 Characterization Conditions m.p. °C 69 4-C1 2,4-diCl H m.p. = 116 70 4-OH 2,4-diCl F F H m.p. = 196 71 4-0S02-nPr 2,4-diCl F F H m.p. = 77 72 4-0S02-nPr 2,4-diCl F F S02-nPr m.p. =153 The compounds of formula (I) possess very good affinity in vitro (ic50 - J-f 5.10 M) for the CBi cannabinoid receptors, in the experimental conditions described by M. Rinaldi-Carmona et al. (FEBS Letters, 1994, 350, 240-244). 5 The antagonistic character of the compounds of formula (I) was demonstrated by the results obtained in the models of adenylate-cyclase inhibition as described in M. Bouaboula et al., J. Biol. Chem., 1995, 270, 13973-13980, M, Rinaldi-Carmona et al., J. Pharmacol. Exp. Ther., 1996, 278, 871-878 and M. Bouaboula et al., J. Biol. Chem., 1997, 272, 22330-22339. 10 The interaction of a compound according to the invention with the CBj receptors in the brain is determined in the mouse with the test of ex-vivo binding of [3H]-CP55940 after intravenous injection as described in M. Rinaldi-Carmona et al., FEBS Letters 1994, 350, 240-244 and M. Rinaldi-Carmona et al., Life Sciences 1995, 56. 1941-1947. 15 The interaction of a compound according to the invention with the CBi receptors in the periphery is determined in the mouse with the test of reversal of the inhibitory effect of CP55940 on gastrointestinal transit after oral administration as described in M. Rinaldi-Carmona et al., J. Pharmacol. Exp. Ther., 2004, 310. 905-914. The toxicity of the compounds of formula (I) is compatible with their use as 20 medication. 1253799-1 INTELLECTUAL PROPERTV OFFICE OF N Z t U dec 2007 RECEIVED 44 Thus, according to another of its aspects, the invention relates to medicinal products for human or veterinary medicine which contain a compound of formula (I), or an acid addition salt with a pharmaceutically acceptable acid, or alternatively a solvate or a hydrate of the compound of formula (I). 5 Thus, the compounds according to the invention can be used in the treatment or prevention of diseases involving the CBi cannabinoid receptors, in humans or in animals notably in mammals including without limitation dogs, cats, horses, cattle and sheep. For example, and without limitation, the compounds of formula (I) can be used as 10 psychotropic medicinal products, notably for the treatment of psychiatric disorders including anxiety, depression, mood disorders, insomnia, delusional disorders, obsessive disorders, psychoses in general, schizophrenia, attention deficit hyperactivity disorder (ADHD) in hyperactive children as well as for the treatment of disorders associated with the use of psychotropic substances, notably in the case of 15 substance abuse and/or dependence on a substance, including alcohol addiction and nicotine addiction. The compounds of formula (I) according to the invention can be used as medicinal products for the treatment of migraine, stress, diseases of psychosomatic origin, panic attacks, epilepsy, motor disorders, in particular dyskinesias or 20 Parkinson's disease, tremor and dystonia. The compounds of formula (I) according to the invention can also be used as medicinal products in the treatment of memory disorders, cognitive disorders, in particular in the treatment of senile dementias, of Alzheimer's disease, as well as in the treatment of attention or vigilance disorders. 25 Moreover, the compounds of formula (I) can be used as neuroprotectors, in the treatment of ischaemia, head injuries and the treatment of acute or chronic neurodegenerative diseases: including chorea, Huntington chorea, Tourette syndrome. The compounds of formula (I) according to the invention can be used as medicinal products in the treatment of pain: neuropathic pain, acute peripheral pain, 30 chronic pain of inflammatory origin, pain induced by anticancer treatment. The compounds of formula (I) according to the invention can be used as medicinal products in human or veterinary medicine in the prevention and treatment of disorders of appetite, craving (for sugars, carbohydrates, drugs, alcohols or any appetizing substance) and/or eating disorders, notably for the treatment of obesity or 35 of bulimia as well as for the treatment of type II diabetes or non-insulin-dependent diabetes and for the treatment of dyslipidaemias, and of metabolic syndrome. Thus, 1253799-1 INTELLECTUAL PROPERTV OFFICE OF N.Z 1U DtC 2007 RECEIVED 45 the compounds of formula (I) according to the invention can be used in the treatment of obesity and of the risks associated with obesity, notably cardiovascular risks. Moreover, the compounds of formula (I) according to the invention can be used as medicinal products in the treatment and prevention of gastrointestinal disorders, 5 diarrhoea, ulcers, vomiting, bladder and urinary disorders, liver diseases such as chronic cirrhosis, fibrosis, hepatic steatosis, steatohepatitis, as well as disorders of endocrine origin, cardiovascular disorders, hypotension and atherosclerosis, haemorrhagic shock, septic shock, asthma, chronic bronchitis, chronic obstructive pulmonary diseases, Raynaud syndrome, glaucoma, fertility disorders, premature 10 labour, abortion, inflammatory phenomena, immune system diseases, in particular autoimmune and neuroinflammatory such as rheumatoid arthritis, reactive arthritis, diseases resulting in demyelinization, multiple sclerosis, infectious and viral diseases such as encephalitis, cerebrovascular accidents and as medicinal products for anticancer chemotherapy, for the treatment of Guillain-Barre syndrome and for the 15 treatment of bone diseases and osteoporosis. According to the present invention, the compounds of formula (I) can be used quite particularly for the preparation of medicinal products for use in the prevention and treatment of psychotic disorders, in particular schizophrenia, attention deficit hyperactivity disorders (ADHD) in hyperactive children; for the prevention and 20 treatment of memory disorders and cognitive disorders; for the treatment of alcohol dependence, nicotine dependence, for giving up drinking alcohol and smoking; acute or chronic neurodegenerative diseases. More particularly, the compounds of formula (I) according to the present invention can be used in the treatment and prevention of disorders of appetite, 25 metabolic disorders, gastrointestinal disorders, inflammatory phenomena, immune system diseases, psychotic disorders, alcohol dependence, and nicotine dependence. According to one of its aspects, the present invention relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, a hydrate, or a solvate thereof for the treatment of the disorders and diseases stated above. 30 According to another of its aspects, the present invention relates to pharmaceutical compositions containing, as active principle, a compound according to the invention. These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, a solvate or hydrate of said compound, as well as at least one pharmaceutically 35 acceptable excipient. 1253799-1 INTELLECTUAL PROPERTV OFFICE OP N.Z t U DEC 2007 RECEIVED 46 10 15 20 • 25 30 Said excipients are selected depending on the pharmaceutical form and the desired method of administration, from the usual excipients that are known by a person skilled in the art. The pharmaceutical compositions according to the present invention can contain, alongside a compound of formula (I), one or more other active principle(s) that can be used in the treatment of the disorders and diseases stated above. Thus, the present invention also relates to pharmaceutical compositions containing a compound of formula (I) according to the present invention combined with one or more active principle(s) selected from one of the following therapeutic classes: - another antagonist of the CBi cannabinoid receptors; - a modulator of the CB2 cannabinoid receptors; - an antagonist of the AT 1 angiotensin II receptors; - an inhibitor of the converting enzyme; - a calcium antagonist; - a diuretic; - a beta-blocker; - an antihyperlipaemic agent or an antihypercholesterolaemic agent; - an antidiabetic agent; - another anti-obesity agent or agent acting on metabolic disorders; - a nicotinic agonist, a partial nicotinic agonist; - an antidepressant, an antipsychotic, an anxiolytic; - an anticancer agent or antiproliferative agent; - an opioid antagonist; as well as: - a memory-improving agent; - an agent for use in the treatment of alcoholism or of withdrawal symptoms; - an agent that can be used for treating osteoporosis; - a non-steroidal or steroidal anti-inflammatory drug; - an anti-infectious agent; - an analgesic; - an antiasthmatic agent. "Antagonist of the ATi angiotensin II receptors" means a compound such as candesartan cilexetil, eprosartan, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, valsartan, and each of these compounds can itself be combined with a diuretic such as hydrochlorothiazide. INTELLECTUAL PROPERTV OFFICE OP M.Z ? U DEC 200/ 1253799-1 47 "Inhibitor of the converting enzyme" means a compound such as alacepril, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, temocapril, trandolapril, zofenopril, and each of these compounds can itself be combined with a diuretic such as hydrochlorothiazide or indapamide or with a calcium antagonist such as amlodipine, diltiazem, felodipine or verapamil. "Calcium antagonist" means a compound such as amlodipine, aranidipine, benidipine, bepridil, cilnidipine, diltiazem, efonidipine hydrochloride ethanol, fasudil, felodipine, isradipine, lacidipine, lercanidipine hydrochloride, manidipine, mibefradil hydrochloride, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, terodiline, verapamil. "Beta-blocker" means a compound such as acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bunitrolol, butofilolol, carazolol, carteolol, carvedilol, cloranolol, epanolol, esmolol, indenolol, labetalol, landiolol, levobunolol, levomoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, nipradilol, oxprenolol, penbutolol, pindolol, propranolol, salmeterol, sotalol, talinolol, tertalol, tilisolol, timolol, xamoterol, xibenolol. "Antihyperlipaemic or antihypercholesterolaemic agent" means a compound selected from the fibrates such as alufxbrate, beclobrate, bezafibrate, ciprofibrate, clinofibrate, clofibrate, etofibrate, fenofibrate; the statins (HMG-CoA reductase inhibitors), such as atorvastatin, fluvastatin sodium, lovastatin, pravastatin, rosuvastatin, simvastatin, or a compound such as acipimox, aluminium nicotinate, azacosterol, cholestyramine, dextrothyroxine, meglutol, niceritrol, nicoclonate, nicotinic acid, beta-sitosterol, tiadenol. "Antidiabetic agent" means a compound belonging to one of the following classes: sulphonylureas, biguanidines, alpha glucosidase inhibitors, thiazolidinediones, metiglinides, such as acarbose, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, gliquidone, glisoxepide, glybuzole, glymidine, metahexamide, metformin, miglitol, nateglinide, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide, troglitazone, foliose, as well as insulin and insulin analogues. "Other anti-obesity agent or agent acting on metabolic disorders" means a compound such as amfepramone, benfluorex, benzphetamine, indanorex, mazindol, mefenorex, methamphetamine, D-norpseudoephedrine, sibutramine, a topiramate, a lipase inhibitor (orlistat cetilistat), a PPAR agonist (peroxisome proliferator activated INTELLECTUAL PROPERTY OFRCF OF M.Z 1 u DEC 2007 RFCFIVFD 48 receptor agonist), a dopamine agonist, a leptin receptor agonist, a serotonin reuptake inhibitor, a beta-3 agonist, a CCK-A agonist, an NPY inhibitor, an MC4 receptor agonist, an MCH (melanin concentrating hormone) receptor antagonist, an orexin antagonist, a phosphodiesterase inhibitor, an inhibitor of 11|3HSD (1 l-(3-hydroxy steroid dehydrogenase), a DPP-IV (dipeptidyl peptidase IV) inhibitor, an antagonist (or inverse agonist) of histamine H3, a CNTF (ciliary neurotrophic factor) derivative, a GHS (growth hormone secretagogue) receptor agonist, a ghrelin modulator, an inhibitor of diacylglycerol acyltransferase (DGAT), a phosphodiesterase (PDE) inhibitor, a thyroid hormone agonist, a glucocorticoid receptor antagonist, an inhibitor of stearoyl-CoA-desaturase (SCD), a modulator of transporters of phosphate, of glucose, of fatty acid, of dicarboxylate, a 5HT2 antagonist, a 5HT6 antagonist, a bombesine agonist. "Opioid antagonist" means a compound such as naltrexone, naloxone or nalmefene. "Agent for use in the treatment of alcoholism as well as withdrawal symptoms" means acamprosate, the benzodiazepines, beta-blockers, clonidine, carbamazepine. "Agent for use in the treatment of osteoporosis" means for example the bisphosphonates such as etidronate, clodronate, tiludronate, risedronate. According to the present invention, it is also possible to combine other compounds having antihyperlipaemic, antihypercholesterolaemic, antidiabetic or anti-obesity properties. More particularly it is possible to combine compounds belonging to one of the following classes: inhibitors of PTP IB (protein tyrosine phosphase-lB), VPAC-2 receptor agonists, GLK modulators, retinoid modulators, inhibitors of glycogen phosphorylase (HGLPa), glucagon antagonists, glucose-6-phosphate inhibitors, activators of pyruvate dehydrogenase kinase (PKD), modulators of RXR, FXR, LXR, inhibitors of SGLT (sodium-dependent glucose transporter), inhibitors of CETP (cholesteryl ester transfer protein), inhibitors of squalene synthetase, inhibitors of squalene epoxidase, inhibitors of triglyceride synthesis, inducers of LDL (low-density lipoprotein) receptors, inhibitors of IB AT, inhibitors of FBPase (fructose-1,6-biphosphatase), modulators of CART (cocaine-amphetamine-regulated transcript), MC4 (melanocortin 4) modulators, orexin receptor antagonists. According to another aspect of the invention, the compound of formula (I), one of its pharmaceutically acceptable salts or one of their solvates and the other combined active principle can be administered simultaneously, separately or spread over time. INTELLECTUAL PROPERTV OFFICE OF Nl Z IU DEC 2007 RF^cl VF=D 49 "Simultaneous use" means administration of the compounds of the composition according to the invention contained in one and the same pharmaceutical form. "Separate use" means administration, at the same time, of the two compounds of the composition according to the invention each contained in a separate 5 pharmaceutical form. "Use spread over time" means the successive administration, of the first compound of the composition of the invention, contained in one pharmaceutical form, then of the second compound of the composition according to the invention, contained in a separate pharmaceutical form. In this case, the period of time that passes between 10 administration of the first compound of the composition according to the invention and administration of the second compound of the same composition according to the invention does not generally exceed 24 hours. In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, 15 transdermal or rectal administration, the active principle of formula (I) above, or optionally its salt, solvate or hydrate, can be administered in a unit form of administration, mixed with conventional pharmaceutical excipients, to animals and to human beings for the prophylaxis or treatment of the aforementioned disorders or diseases. 20 The appropriate unit forms of administration comprise the forms by the oral route such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, forms for sublingual, buccal, intratracheal, intraocular, intranasal or inhalation administration, forms for topical, transdermal, subcutaneous, intramuscular or intravenous administration, forms for rectal administration, and implants. For 25 topical application, the compounds according to the invention can be used in creams, gels, ointments or lotions. As an example, a unit form of administration of a compound according to the invention in the form of a tablet can contain the following components: Compound according to the invention : 50.0 mg 30 Mannitol : 223.75 mg Croscarmellose sodium : 6.0 mg Maize starch : 15.0 mg Hydroxypropylmethylcellulose : 2.25 mg Magnesium stearate : 3.0 mg 35 By the oral route, the dose of active principle administered per day can reach 0.01 to 100 mg/kg, in one or more doses, preferably 0.02 to 50 mg/kg. 1253799-1 INTELLECTUAL PROPERTY OFPICF nr m ? I u DEC 2007 </div>

Claims

<div class="application article clearfix printTableText" id="claims"> 50 There may be special cases where higher or lower doses are appropriate; such doses are still within the scope of the invention. In accordance with usual practice, the dosage appropriate to each patient is determined by the doctor depending on the method of administration, and the weight and response of said patient. Described herein is a method of treatment of the pathologies stated above that comprises the administration, to a patient, of an effective dose of a compound according to the invention, or a pharmaceutically acceptable salt, or a hydrate or a solvate thereof. 1253799-1 INTELLECTUAL PROPER"'' -OFPICF or M.7 1 u dec 2007 RECEIVED 51 WHAT WE CLAIM IS:

1. A compound of formula (I): R. '3 iT i2 II CH?—N—S—R 2 II .N r4 N (I) R. 5 in which: - Rj represents . a (C]-ci2)alkyl, unsubstituted or substituted one or more times with substituents selected independently from a fluorine atom, a hydroxyl, a (Ci-c4)alkoxy, a (Ci-c4)alkylthio, a phenoxy, a trifluoromethoxy radical, a difluoromethoxy radical, a difluoromethylthio radical, a trifluoromethylthio radical; . a non-aromatic (c3-c12) carbocyclic radical, unsubstituted or substituted one or more times with substituents selected independently from a (Ci-c4)alkyl, a (Ci-c4)alkoxy, a (Ci-c4)alkylthio, a fluorine atom, a hydroxyl, a trifluoromethyl radical, a difluoromethyl radical, a trifluoromethoxy radical, a difluoromethoxy, a trifluoromethylthio radical, a difluoromethylthio radical; . a methyl substituted with a non-aromatic (c3-c12) carbocyclic radical, unsubstituted or substituted one or more times with substituents selected independently from a (Ci-c4)alkyl, a (Ci-c4)alkoxy, a (Ci-c4)alkylthio, a fluorine atom, a hydroxyl, a trifluoromethyl radical, a difluoromethyl radical, a trifluoromethoxy radical, a difluoromethoxy radical, a trifluoromethylthio radical, a difluoromethylthio radical; . a phenyl, benzyl, benzhydryl, or benzhydrylmethyl radical, in which each phenyl group is unsubstituted or substituted one or more times with substituents selected independently from a halogen atom, a hydroxyl, a methylenedioxy, a cyano, a nitro, a (Ci-c4)alkylcarbonyl group or an Alk, OAlk, S(0)nAlk or 0S(0)nAlk group; . a phenyl radical substituted with a heterocyclic radical selected from pyrrolyl, imidazolyl, pyridyl or pyrazolyl, said heterocyclic radical being unsubstituted or substituted one or more times with one or more substituents selected independently from a halogen atom or a (Ci-c4)alkyl group; INTELLECTUAL PROPERTY OFPICE OF ^ i 1253799-1 11) dp; 2(8/ I R FT c 52 . a phenyl radical substituted with a phenyl or a phenoxy in which each phenyl group is unsubstituted or substituted one or more times with substituents selected independently from a halogen atom, a hydroxyl, a methylenedioxy, a cyano, a nitro, a (Ci-c4)alkylcarbonyl group or an Alk, OAlk, S(0)nAlk or 0S(0)nAlk group; . a thienyl, furyl, oxazolyl, thiazolyl, imidazolyl, pyrrolyl, or pyridyl radical, said radical being unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (C]-c4)alkyl, a trifluoromethyl group; . a tetrahydronaphthalenyl or a naphthyl unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Ci-c4)alkyl, a di(Ci-c4)alkylamino or a trifluoromethyl group; . a 2,3-dihydrobenzofuranyl unsubstituted or substituted one or more times with a (Ci-c4)alkyl group; . an indol-2-yl or an N-methylindol-2-yl; - R.2 represents a hydrogen atom, a (Ci-c4)alkyl or a (Cj-c4)alkylsulphonyl group; - R3 represents a cyano, a hydroxyl, a (Ci-c4)alkoxy, a cyanomethyl, a hydroxymethyl, a (Ci-c4)alkoxymethyl, a fluoromethyl, a tetrazolylmethyl, an N-(methyl)tetrazolylmethyl, a tetrazolyl, an N-(methyl)tetrazolyl, a CONR6R7 group, a CH2S(0)n(Ci-C4)alkyl group, a COORg group or a CH2NRJI7 group; - R4 and R5 each represent independently a phenyl unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Ci-c7)alkyl group unsubstituted or substituted one or more times with a fluorine atom, an OAlk, S(0)nAlk or 0S(0)nAlk group; - Rg and r7 each represent independently a hydrogen atom or a (Ci-c4)alkyl or R6 and R7 together with the nitrogen atom to which they are bound constitute a heterocyclic radical selected from pyrrolidinyl, piperidinyl, morpholinyl, and piperazinyl unsubstituted or substituted one or more times with a (Ci-c4)alkyl; - Rg represents a (Ci-c4)alkyl; - n represents 0, 1 or 2; - Alk represents a (C]-c4)alkyl unsubstituted or substituted one or more times with a fluorine atom; or an acid addition salt, a hydrate, or a solvate thereof.

2. A compound according to Claim 1 in which: - Ri represents . a (Ci-C7)alkyl; 1253799-1 INTELLECTUAL PROPERTV OFFICE OP M2 1 (J DEC 2007 RECEIVED 53 . a (c3-c7)cycloalkyl unsubstituted or substituted one or more times with a (Ci-c4)alkyl group; . a (c3-c7)cycloalkylmethyl unsubstituted or substituted one or more times on the carbocycle with a (Ci-c4)alkyl; 5 . a phenyl unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Ci-c4)alkyl, a (Ci-c4)alkoxy, a cyano, a trifluoromethyl group, a trifluoromethoxy group, an S(0)nAlk group, a (Ci-c4)alkylcarbonyl group, a phenyl; . a benzyl unsubstituted or substituted with one or more substituents selected 10 independently from a halogen atom, a (Ci-c4)alkyl, a (Ci-c4)alkoxy; a trifluoromethyl group; . a thienyl, furyl, oxazolyl, thiazolyl, or imidazolyl radical, said radical being unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Ci-c4)alkyl, a trifluoromethyl group; 15 .a naphthyl unsubstituted or substituted with one or more substituents selected independently from a (C]-c4)alkyl, a di(C]-c4)alkylamino; . a 2,3-dihydrobenzofuranyl unsubstituted or substituted one or more times with a (CrC4)alkyl group; - R.2 represents a hydrogen atom or a (Ci-c4)alkyl; 20 - R.3 represents a cyano, a hydroxyl, a (Ci-c4)alkoxy, a cyanomethyl, a hydroxymethyl, a (Ci-c4)alkoxymethyl, a fluoromethyl, a tetrazolylmethyl, an N-(methyl)tetrazolylmethyl, a tetrazolyl, an N-(methyl)tetrazolyl, a CONR6R7 group, a ch2s(0)nAlk group, a COORg group; - R4 and R5 each represent independently a phenyl unsubstituted or substituted 25 with one or more substituents selected independently from a halogen atom, a (Ci-C7)alkyl, a (Ci-c4)alkoxy, a trifluoromethyl group or an S(0)nAlk group; - Rg and R7 each represent independently a hydrogen atom or a (Ci-c4)alkyl or R6 and R7 together with the nitrogen atom to which they are bound constitute a heterocyclic radical selected from pyrrolidinyl, piperidinyl, morpholinyl, and 30 piperazinyl unsubstituted or substituted one or more times with a (Ci-c4)alkyl; - Rg represents a (Cj-COalkyl; - n represents 0, 1 or 2; - Alk represents a (Ci-c4)alkyl; or an acid addition salt, a hydrate, or a solvate thereof. 35

3. A compound of formula (I), as defined in Claim 1, wherein R3 is a cyano and the substituents R], R2, R4, R5 are as defined in Claim 1. 1253799-1 INTELLECTUAL PROPERTY OFFICE OF NZ I u DtC 200? RECEIVED 54

4. A compound of formula (I), as defined in Claim 1, wherein R3 is a hydroxyl and the substituents Ri, R2, r4, R5 are as defined in Claim 1.

5. A compound of formula (I), as defined in Claim 1, wherein R3 is a (CpC^alkoxy and the substituents Rj, R2, R4, R5 are as defined in Claim 1. 5

6. A compound of formula (I), as defined in Claim 1, wherein R3 is a (Ci-c4)alkoxymethyl and the substituents Ri, R2, r4, R5 are as defined for the compounds of formula (I) in Claim 1.

7. A compound of formula (I), as defined in Claim 1 , wherein R3 is a CONR6R7 group and the substituents Ri, R2, Rt, r5, R6 and R7 are as defined in Claim 1. 10

8. A compound of formula (I), as defined in Claim 1 , wherein R3 is a COORg and the substituents Ri, R2, R4, R5 and Rg are as defined in Claim 1.

9. A compound of formula (I), as defined in Claim 1 , wherein R3 is a tetrazol-1-ylmethyl or a tetrazol-2-ylmethyl and the substituents Ri, R2, Rt, R5 are as defined in Claim 1. 15

10. A compound according to Claim 1 in which: - Ri represents: . a phenyl, benzyl, benzhydryl, or benzhydrylmethyl radical, in which each phenyl group is unsubstituted or substituted one or more times with substituents selected independently from a halogen atom, a hydroxyl, a (Ci-c4)alkyl, a (Ci-c4)alkoxy, 20 a methylenedioxy, a cyano, a nitro, a trifluoromethyl, a difluoromethyl, a difluoromethoxy, a trifluoromethoxy, a trifluoromethylthio, a difluoromethylthio, an S(0)nAlk group, an 0S(0)„Alk group, a (Ci-c4)alkylcarbonyl group; . a furyl radical unsubstituted or substituted with one or more substituents selected independently from a halogen atom, a (Ci-c4)alkyl, a trifluoromethyl group; 25 - R2 represents a hydrogen atom or a (Ci-c4)alkylsulphonyl group; -r3 represents a cyano, a hydroxyl, a (Ci-c4)alkoxy, a hydroxymethyl, a (Ci-c4)alkoxymethyl, a CONR^R? group, a COORg group, a tetrazol- 1-yl methyl or a tetrazol-2-ylmethyl, the groups R6, r7, Rs being as defined in Claim 1; - R4 represents a 4-chlorophenyl, a 4-methoxyphenyl or a 4-0S02-Alk, Alk 30 representing a (Ci-c4)alkyl unsubstituted or substituted one or more times with a fluorine atom; - R5 represents a 2-chlorophenyl, a 2-bromophenyl or a 2,4-dichlorophenyl; or an acid addition salt, a hydrate, or a solvate thereof.

11. A compound according to Claim 1 in which: 35 - Ri represents a 3-chlorophenyl, 3-fluorophenyl, 3,6-difluorophenyl, 2,6-difluorophenyl, 3-methoxyphenyl, 3-trifluoromethylphenyl, INTELLECTUAL. propertv officf OF w.z 1 U DEC 2007 1253799-1 RECEIVED 55 3-trifluoromethoxyphenyl, a benzyl, a 4-trifluoromethylbenzyl or a 2-trifluoromethyl-4-methylfuryl group; - R.2 represents a hydrogen atom; - R3 represents a cyano, methoxy or dimethylaminocarbonyl group; - R4 represents a 4-chlorophenyl, a 4-methoxy or a 4-propanesulphonyloxy; - R5 represents a 2,4-dichlorophenyl or a 2-chlorophenyl; or an acid addition salt, a hydrate, or a solvate thereof.

12. A compound according to Claim 1, selected from: - N-{[5-(4-chlorophenyl)-4-cyano-l -(2,4-dichlorophenyl)-1//-pyrazol-3 -yl]methyl} -3-cyanobenzenesulphonamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1//-pyrazol-3-yl] methyl} -3 -trifluorobenzenesulphonamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1H-pyrazol-3 -yljmethyl} -2-trifluoromethoxybenzenesulphonamide, - N- {[5 -(4-chlorophenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1 //-pyrazol-3 -yl]methyl}-3-methoxybenzenesulphonamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1 //-pyrazol-3-yljmethyl} -3 -chlorobenzenesulphonamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2-chlorophenyl)-1 //-pyrazol-3-yl]methyl}-3 -fluorobenzenesulphonamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2-chlorophenyl)-1 //-pyrazol-3-yljmethyl}-2-fluorobenzenesulphonamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2-chlorophenyl)-1H-pyrazol-3 -yljmethyl} -2-trifluoromethoxybenzenesulphonamide, - N- {[5-(4-methoxyphenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1 //-pyrazol-3 -yljmethyl} -3.5 -difluorobenzenesulphonamide, - N- {[5-(4-chlorophenyl)-4-methoxy-1 -(2,4-dichlorophenyl)-1 //-pyrazol-3 -yljmethyl} -3-chlorobenzenesulphonamide, - 5 -(4-chlorophenyl)-3 -({[(3 -chlorophenyl)sulphonyl J amino} methyl)-1 -(2,4-dichlorophenyl)-iV-methy 1-1 //-pyrazole-4-carboxamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1H- pyrazol-3-y 1J methyl} -1 -pheny lmethanesulphonamide, - N- {[5-(4-chlorophenyl)-4-cyano-1 -(2,4-dichlorophenyl)-1 //-pyrazol-3 -ylJmethyl}-5-methyl-2-(trifluoromethyl)furan-3-sulphonamide; or an acid addition salt, a hydrate, or a solvate thereof. 1253799-1 INTELLECTUAL PROPERTY OFRCF OF M7 I u dec 200? RF^?=!VED 56

13. A method of preparing a compound of formula (I), as defined in Claim 1, wherein a compound of formula (ii): R, I ch2-nh (ii) "5 in which R2, r4, r5 are as defined in Claim 1 and R3 represents R3 or a precursor of r3, is reacted, in the presence of a base, in a solvent, with a sulphonyl halide of formula HalSC^Ri, in which Ri is as defined in Claim 1 and Hal represents a halogen atom; and if applicable, the compound obtained of formula (iii): f2 r\ ^ch2-n-so2-r, w R4 n (III) r5 in which R'3 is R3 or is a precursor of r3, is converted to a compound of 10 formula (i).

14. A compound of formula (i) according to any one of the Claims 1 to 12, or an acid addition salt, a hydrate, or a solvate thereof, for use as a medicament.

15. A pharmaceutical composition, comprising a compound of formula (i) according to any one of the Claims 1 to 12, or an acid addition salt, a hydrate, or a solvate 15 thereof, and at least one pharmaceutically acceptable excipient.

16. Use of a compound of formula (i) as defined in Claims 1 to 12, for the preparation of a medicinal product for the treatment or the prevention of a disease in which the CBi receptors are involved.

17. Use according to Claim 16, wherein the disease is selected from the group 20 consisting of: psychiatric disorders, substance dependence and withdrawal, cognitive disorders, disorders of attention and vigilance, and acute and chronic neurodegenerative diseases.

18. Use according to Claim 16, wherein the disease is selected from the group consisting of: metabolic disorders, disorders of craving, disorders of appetite, 25 obesity, type ii diabetes, metabolic syndrome, and dyslipidaemia. 1253799-1 INTELLECTUAL PROPERTY OFFICE OF N.Z. 1U DEC 200/ 57

19. Use according to Claim 16, wherein the disease is elected from the group consisting of: pain, neuropathic pain, and pain induced by anticancer treatment.

20. Use according to Claim 16, wherein the disease is selected from the group consisting of: gastrointestinal disorders, vomiting, diarrhoea, ulcers, and liver 5 diseases.

21. Use according to Claim 16, wherein the disease is selected from the group consisting of: diseases of the immune system, rheumatoid arthritis, demyelinization, multiple sclerosis, and inflammatory diseases.

22. Use according to Claim 16, wherein the disease is selected from the group 10 consisting of: Alzheimer's, Parkinson's, schizophrenia, cognitive disorders, diabetes, obesity, metabolic syndrome and tobacco withdrawal.

23. A compound of formula (I), as defined in Claim 1, when prepared by a method as claimed in Claim 13.

24. A compound, as defined in Claim 1 or as claimed in Claim 14 or 23, substantially 15 as herein described with reference to any example thereof.

25. A pharmaceutical composition, as claimed in Claim 15, substantially as herein described with reference to any example thereof.

26. Use, as defined in Claim 16, substantially as herein described with reference to any example thereof. end of claims 1253799-1 INTELLECTUAL PROPER"' » OFPICF OF w/' 1 U DEC 200/ R F r p t s< E D </div>